Differential gene expression screening uncovers downregulation of the cell cycle regulator BTG2 as an important step in renal tumor biology by Struckmann, Kirsten
 1
Differential gene expression screening uncovers downregulation of 
the cell cycle regulator BTG2 as an important step 
in renal tumor biology 
 
 
 
 
Inauguraldissertation 
 
 
 
 
zur Erlangung der Würde eines Doktors der Philosophie 
 
vorgelegt der 
 
Philosophisch-Naturwissenschaftlichen Fakultät 
 
der Universität Basel 
 
 
 
von 
 
 
 
Kirsten Struckmann 
 
aus Deutschland 
 
 
 
Basel, 2003 
 2
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
 
auf Antrag von  
 
 
Prof. Dr. med Christoph Moroni (Fakultätsverantwortlicher) 
 
Prof. Dr. Nancy Hynes (Korreferentin) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basel, den 21.10.2003 
 
 
 
  Prof. Dr. Matthias Tanner (Dekan) 
    
               
 3
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meinen Eltern Dieter und Christel Struckmann 
Contents 
 4
CONTENTS 
I ACKNOWLEDGEMENTS...................................................................................................6 
II ABBREVIATIONS ................................................................................................................7 
III ABSTRACT ........................................................................................................................8 
1 INTRODUCTION................................................................................................................10 
1.1 EPIDEMIOLOGY OF RENAL CELL CANCER.........................................................................10 
1.2 ETIOLOGY OF RCC..........................................................................................................11 
1.3 PROGNOSIS OF RCC ........................................................................................................11 
1.4 THERAPEUTICAL APPROACHES FOR RCC ........................................................................12 
1.5 PROGNOSTIC PARAMETERS IN RCC.................................................................................12 
1.6 CLEAR CELL RENAL CELL CARCINOMA (CRCC) ..............................................................16 
1.6.1 Histopathology of cRCC.........................................................................................16 
1.6.2 Cytogenetic and molecular alterations in cRCC....................................................16 
1.6.3 Molecular carcinogenesis of cRCC........................................................................19 
1.7 CDNA AND TISSUE MICROARRAY TECHNOLOGIES FOR THE IDENTIFICATION OF CRCC 
RELEVANT GENES ........................................................................................................................20 
1.8 AIM OF THE THESIS..........................................................................................................21 
2 MATERIAL AND METHODS...........................................................................................23 
2.1 CELL CULTURE ................................................................................................................23 
2.2 RNA EXTRACTION ..........................................................................................................23 
2.3 CDNA ARRAY EXPERIMENTS ..........................................................................................25 
2.4 RNA IN SITU HYBRIDIZATION ON FROZEN RENAL TISSUE MICROARRAYS.........................26 
2.5 CLONING OF BTG2 AND G3PDH SEQUENCES .................................................................29 
2.6 NORTHERN BLOT ANALYSIS.............................................................................................32 
2.7 QUANTIFICATION OF BTG2 MRNA COPY NUMBERS USING THE LIGHTCYCLER ..............34 
2.7.1 General aspects of quantitative PCR using the LightCycler system......................34 
2.7.2 Generation of standard curves from BTG2 and G3PDH in vitro transcripts........36 
2.8 BTG2 MRNA EXPRESSION IN PRIMARY CRCC AND NORMAL RENAL TISSUE...................39 
2.9 INDUCIBILITY OF BTG2 MRNA EXPRESSION IN CRCC CELL LINES .................................40 
3 RESULTS..............................................................................................................................41 
3.1 CDNA ARRAY ANALYSIS.................................................................................................41 
3.2 RNA IN SITU HYBRIDIZATION ..........................................................................................43 
3.3 MOLECULAR STUDIES ON BTG2 TO EVALUATE ITS IMPORTANCE FOR CRCC BIOLOGY ...50 
3.3.1 Northern blot analysis............................................................................................52 
3.3.2 BTG2 mRNA expression in primary cRCC and normal renal tissue evaluated by 
quantitative RT-PCR ..............................................................................................................53 
3.3.3 Modulation of BTG2 mRNA expression in cRCC cell lines ...................................56 
4 DISCUSSION .......................................................................................................................61 
4.1 COMBINATION OF CDNA AND TISSUE MICROARRAY TECHNOLOGIES FOR THE 
IDENTIFICATION OF CRCC RELEVANT GENES ..............................................................................61 
Contents 
 5
4.2 BTG2 – A NEW CANDIDATE GENE FOR RENAL TUMOR BIOLOGY? ....................................66 
4.3 CONCLUSION...................................................................................................................74 
5 APPENDIX ...........................................................................................................................76 
6 LITERATURE .....................................................................................................................78 
7 CURRICULUM VITAE......................................................................................................98 
 
Acknowledgements 
 6
I Acknowledgements 
 
First of all, I want to thank Prof. Dr. med. Michael J. Mihatsch for hosting and supporting my 
work at the Institute of Pathology. 
 
I am very grateful to Prof. Dr. med Holger Moch for giving me the opportunity to work in his 
group, for his excellent supervision during the whole time of my PhD work, and for informative 
discussions about the pathobiology of renal cancer. 
 
My special thanks go to the members of my thesis committee, Prof. Dr. med. Christoph Moroni 
and Dr. Nancy Hynes for providing excellent advice and for very helpful discussions.  
 
I am deeply thankful to Dr. Peter Schraml and Dr. Ronald Simon because they teached me so 
many things about research work, they always had time for fruitful discussion, and they 
supported me during the whole time of my PhD thesis. 
 
Thanks to all of the members of the laboratory for their friendship, collegiality, and technical 
assistance. In particular, I would like to thank Alexander Rufle for informative discussions about 
molecularbiological techniques and his professional assistance and also Martina Mirlacher, 
Martina Storz, and Yvonne Knecht for preparing frozen sections and histological stainings 
needed in my thesis. 
 
I also would like to thank Dr. Heide Tullberg who gave me very helpful instructions for my work 
in the cell laboratory. 
 
Finally, I would like to thank my whole family, in particular my parents Dietrich and Christiane 
Struckmann, and Daniele Calvano Forte for supporting me during the whole time of my PhD 
studies.  
Abbreviations 
 7
II Abbreviations 
 
AJCC American Joint Committe on Cancer 
bp base pair 
CAP College of American Pathologists 
CGH Comparative Genomic Hybridization 
chRCC Chromophobe Renal Cell Cancer 
cRCC Clear Cell Renal Cell Cancer 
E Amplification Efficiency 
FISH Fluorescence in situ Hybridization 
H&E staining Hemalaun & Eosin Staining 
IHC Immunohistochemistry 
kb kilobase 
LOH Loss of Heterozygosity 
NCBI National Center for Biotechnology Information 
pRCC Papillary Renal Cell Cancer 
RCC Renal Cell Cancer 
RISH RNA in situ Hybridization 
RT-PCR Reverse Transcription – Polymerase Chain Reaction 
pT category Pathological Tumor category (extension of primary tumor mass) 
TMA Tissue Microarray 
TNM system Tumor, (Lymph -)node, (distant) Metastases system (pathological tumor 
classification system) 
TPA 12-O-tetradecanoylphorbolester-13-acetate 
UICC Union Nationale Contre le Cancer 
Abstract 
 8
III Abstract 
 
Renal cell cancer (RCC) is the most common malignancy affecting the adult kidney. The most 
prevalent RCC subtypes is clear cell RCC (cRCC), which accounts for 75% of all malignant 
lesions. RCC is characterized by an unpredictable clinical course and a poor prognosis. Very little 
is known about molecular alterations involved in initiation and progression of RCC. 
Identification of molecular markers might facilitate diagnosis and outcome predictions and help 
to develop innovative and novel treatment options. For this reason, it was the aim of this thesis to 
identify RCC associated genes. In a first part, potentially renal tumor relevant genes were 
uncovered using a combination of cDNA and tissue microarray technology. In a second part, one 
gene was selected to further evaluate its impact on RCC biology using Northern blot analysis, 
quantitative RT-PCR, and functional studies in cRCC cell lines. 
 
To uncover renal cancer associated genes, gene expression profiles of four cRCC cell lines and 
normal renal tissue were compared using BD AtlasTM Human Cancer 1.2 cDNA microarrays. 
Twenty-five genes were found significantly differentially expressed. To evaluate the relevance of 
those genes for RCC, mRNA expression levels were further studied by RNA in situ hybridization 
on a tissue microarray generated from 61 snap frozen primary RCC and 12 normal renal tissues. 
Five genes (VIM, CD74, CHES1, LITAF, and BTG2) appeared to be highly interesting renal 
carcinogenesis relevant genes. Of those genes, three (CHES1, LITAF, and BTG2) have never 
been associated with renal cancer before. 
 
BTG2, a negative cell cycle regulator, which was expressed in normal renal tissue but 
downregulated in cRCC cell lines and primary cRCCs, was chosen for further experiments. 
Northern blot analysis confirmed the results obtained by cDNA and tissue microarray analysis. 
Quantitative RT-PCR analysis in 42 primary cRCCs and 17 normal renal tissues revealed up to 
44-fold reduced BTG2 mRNA expression in the tumor tissues. Decrease of BTG2 mRNA 
expression was not associated with advanced disease indicating that reduction of BTG2 mRNA 
expression is rather an early event in renal carcinogenesis. In cRCC cell lines, BTG2 mRNA 
expression was weakly inducible by the phorbolester TPA in one of four cultures. In contrast, 
increasing cell densities lead to slightly elevated BTG2 mRNA expression in three of four cRCC 
Abstract 
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cell lines. Importantly, in both experiments BTG2 mRNA levels did not reach values observed in 
normal renal tissue by far. The results obtained in the second part of this thesis strongly suggest 
that downregulation of BTG2 is an important step in renal cancer development. Further 
experiments (allelic deletion, mutation and methylation analysis and also re-expression of BTG2 
in cRCC cell lines) are necessary to show whether BTG2 is a new renal tumor suppressor gene. 
 
In summary, application of high throughput cDNA microarray analysis in combination with 
tissue microarray technology allowed the identification of five genes, which might play a role in 
renal tumor biology. Further studies on BTG2, the most interesting candidate gene, indicate that 
downregulation of BTG2 mRNA expression is an early and important step in renal 
carcinogenesis. More experiments will show whether BTG2 is a new renal tumor suppressor 
gene. 
Introduction 
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1 Introduction 
 
1.1 Epidemiology of renal cell cancer 
 
Renal cell cancer (RCC) is the umbrella term for a family of very heterogenous tumors, which 
were primarily classified based on cytomorphological characteristics and their site of origin (1). 
All RCC subtypes have in common that they are derived from epithelial cells of the renal tubulus 
system (nephron). The most prevalent RCC subtypes are clear cell RCC (cRCC), papillary RCC 
(pRCC), and chromophobe RCC (chRCC) which account for 75%, 10%, and 5% of all malignant 
lesions of the kidney, respectively. Duct-Bellini carcinomas, a very rare and aggressive subtype, 
account for 1% of all renal tumors. Three to five percent of all renal carcinomas remain 
unclassified since they do not fit into any of the mentioned categories. Not only malignant lesions 
but also benign tumors derive from the nephron. Oncocytoma, the most common benign lesion, 
arises from the distal tubulus epithel and accounts for 5% of all renal lesions (2). 
 
Referring to the data provided by Globocan 2000 (www-dep.iarc.fr/globocan/globocan.html), 
RCC accounts for about 2% of all human cancers. It is the most common malignancy affecting 
the adult kidney. For the year 2000, the estimated world-wide incidence was about 189.000 and 
the world-wide mortality was about 91.000. About two-thirds of these cases are diagnosed in 
more developed countries. In Switzerland, the estimated incidence for the year 2000 was about 
880 and the mortality was about 440. Men are more frequently affected by cRCC and pRCC than 
women. In contrast, chRCC is more frequently found in women than in men (3).  
 
There has been a strong increase in the incidence rate of RCC within the past decades. Frequent 
usage of modern abdominal imaging modalities lead to incidental detection particularly of small, 
asymtomatic renal tumors and explain the increasing incidence of RCC. In 1970 merely 10% of 
the renal tumors were diagnosed incidentally whereas in 1998 already 61% were found by 
accident in a routinous check-up (4-6). 
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1.2 Etiology of RCC 
 
According to Dhôte et al. (7), who reviewed more than 100 publications released between 1987 
and 1998, accepted risk factors for renal cancer are heavy smoking and severe obesity. 
Interestingly, both risk factors are sex-linked since smoking leads to a higher incidence of RCC 
in men whereas severe obesity is significantly associated with renal cancer in women. Several 
types of exposure are also thought to be associated with RCC. For instance, workers in the iron, 
steel, glas, and petrol industry are at higher risk of developing RCC. Also, intake of phenacetin 
(analgesic) and thiazidic (antihypertensive drug) has been shown to be associated with renal 
cancer. 
 
1.3 Prognosis of RCC 
 
Among the most common RCC subtypes, cRCCs have the worst prognosis, directly followed by 
pRCCs (5-year-survival-rates 50% and 58%, respectively). In contrast, chRCCs show a 
significantly better outcome. Seventy-eight % of patients affected by chRCC are still alive 5 
years after diagnosis (3). 
 
The prognosis for patients suffered from RCC largely depends on the development of metastases. 
Due to the lack of early symptoms, the percentage of advanced already metastatic tumors at first 
presentation is rather high. Additionally, 40 to 50% of non-metastatic tumors at first presentation 
will metastasize during the course of disease. In 80 to 85% of these cases, metastases occure 
within three years after presentation (8, 9). Frequent sites for dissemination are lung, bone, liver, 
and brain but additional, uncommon sites are typical for renal cancer (8, 10). 
 
Late recurrance after long-term, disease free survival is another peculiarity of renal cancer. 
McNichols et al. (11) found a recurrence rate of 11% in a group of 506 10-year-survivors. 
Therefore, a patient with proven RCC can never be considered cured. 
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1.4 Therapeutical approaches for RCC 
 
Therapy of choice for localized tumors is nephrectomy, which implies the excision of the tumor 
containing kidney and, in case of total nephrectomy, the adrenal gland and auxiliary lymphnodes 
(12). After nephrectomy, the 5-year survival rate of localized, organ-confined RCC is between 
88% and 100% (13).  
 
Once the tumor becomes metastatic, therapy remains a challenge for the oncologist. RCC has 
been shown to be nearly insensitive towards conventional chemo-, hormonal, and radiation 
therapy (14-17). The resistance towards chemotherapeutical agents might be explained by (i) 
presence of the transmembrane drug-transporting p170 glycoprotein (MDR1), which causes 
efflux of the therapeutical drugs from the tumor cells, in a large subset of RCC (18, 19) and (ii) 
the low growth fraction and long doubling time of RCC resulting in a reduced susceptibility of 
renal carcinoma cells to the effects of chemotherapeutic agents (19, 20). 
 
In contrast to conventional therapies, immunotherapy seems to have at least some effect on 
disease progression. The principal cytokines used for RCC therapy are interferon-α and 
interleukin-2 (19). Recently, the overall response rate for interferon-α was 11 to 16% (21, 22). 
Although, duration of response is less than 2 years, some long term survivors have been 
described (21). The objective respones rates for interleukin-2 were between 15% and 20% (23-
25). Among patients with complete or partial response, 60% and 18% were alive 5 years after 
diagnosis, respectively (24).  
 
1.5 Prognostic parameters in RCC 
 
Prognostic factors are used to predict the course of a disease, to choose among different treatment 
options, and to determine patient eligibility for entry into a study. Prognostic parameters have to 
meet many criteria like significant association with clinical course of disease, reproducibility in 
large clinical trials, and independent predictive potential in multivariate statistical analysis before 
they become applicable for clinical purposes. The College of American Pathologists (CAP) 
working classification (26) allows the graduation of prognostic markers into different groups 
based on the respective state of research (Table 1). 
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Table 1: CAP working classification. 
 
Category Definition 
I Well supported by the literature; 
generally used in patient 
managment 
II Extensively studied biologically 
and/or clinically 
 A: Tested in clinical trials 
 B: Biologic and correlative 
studies performed; few clinical 
outcome studies 
III Currently do not meet criteria 
for Category I or Category II 
 
According to the CAP working classification there are only a few Category I prognostic 
parameters for RCC. Those include patient related criteria like symptomatic presentation 
(hematuria, pain, palpable tumor mass) and more than 10% body weight loss and also 
conventional macro- and microscopical parameters like for instance occurance and localization of 
metastasis, tumor stage and grade of nuclear differentiation (27). 
 
To date, the most significant factor in prognosis of RCC continues to be tumor stage, which 
reflects the anatomical spread of the disease at presentation (28). Two staging systems, one 
developed by Robson et al. (29) and the TNM system provided and regularly revised by the 
Union Nationale Contre le Cancer and the American Joint Committee on Cancer (AJCC) (30) 
are frequently used in pathological institutions worldwide. The TNM system, which is applied at 
our institute, divides renal tumors into four different groups (I-IV) depending on tumor size and 
extension (pT category) and occurance of lymphnode (pN category) and/or distant metastasis 
(pM category). Following the TNM guidlines (Table 2), 5-year and 10-year survival rates are 
94% and 91.6% in stage I tumors, 89.7% and 78% in stage II, 63.4% and 46.4% in stage III, and 
28% and 16.3% in stage IV lesions (31). However, assessment of the metastatic status is often 
impossible. For those cases tumor extension (T category) alone is also a reliable marker for 
outcome predictions due to its significant association with the survival time (3). 
 
Second in importance, but also significantly associated with patient survival, is the grade of 
nuclear differentiation or tumor grade (3, 28). Already in 1971 Skinner et al. has directed 
attention to the correlation of nuclear features, like size, content, and shape, with patient survival 
Introduction 
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(4). Today, the 4-tired grading system developed by Fuhrman (32) and the 3-tired system 
provided by Thoenes (1) are the most frequently used systems for the grading of renal tumors. At 
our institute the Thoenes grading system is used, which separates RCC in highly differentiated 
(grade 1), moderately differentiated (grade 2), and poorly differentiated (grade 3) tumors. Grade 
1 lesions have a significantly better prognosis than grade 2 and grade 3 tumors (3). 
 
The prognostic potential of tumor stage and grade is universally accepted in the literature and 
both parameters are generally applied in clinical practice. However, these conventional 
histopathological markers obviously have limitations since unfavourable clinical courses of renal 
tumors that were originally thought to have a good prognosis are common (13, 33-35). 
 
Table 2: TNM staging system. 
 
pT-, pN-,  
and pM-
category 
Definition 1
pTX Primary tumor cannot be assessed 
pT0 No evidence of primary tumor 
pT1 Tumor < 7 cm, limited to the kidney 
pT2 Tumor > 7 cm limited to the kidney 
pT3 Tumor extends into major veins, adrenal 
gland or perinephric tissues but not beyond 
Gerota facia 
pT4 Tumor invades beyond Gerota facia 
pNX Regional lymph nodes cannot be assessed 
pN0 No regional lymph node metastasis 
pN1 Metastasis in a single regional lymph node 
pN2 Metastasis in more than one regional lymph 
node 
pMX Distant metastasis cannot be assessed 
pM0 No distant metastasis 
pM1 Distant metastasis 
Tumor stage pT; pN; pM combination 
I pT1; pN0; pM0 
II pT2; pN0; pM0 
III pT1; pN1; pM0 
 pT2; pN1; pM0 
 pT3; pN0 or pN1; pM0 
IV pT4; pN0 or pN1; pM0 
 any pT; pN2; pM0 
 any pT; any pN; pM1 
1 Gerota facia: tough, fibrous membrane surrounding the perinephric fat. 
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In addition to the limited number of histopathological markers, identification of molecular 
markers may help to individually predict disease outcome in RCC. The Ki-67 antigene is widely 
used as a proliferation marker in histopathology. The nuclear protein is not detectable during G0 
and early G1 phase but accumulates during G1 to M phase (36). Ki-67 is suggested to play a role 
in chromosome condensation, sister chromatid separation, and in the control of higher order 
chromatin structure (36-38). Its applicability as an independent prognostic parameter has already 
been shown for prostate and breast cancer (36). Plenty of studies have been done concerning the 
usability of Ki-67 as a prognostic parameter for RCC. Some groups could show that increased 
expression of Ki-67 is also a powerfull, independent prognostic marker associated with adverse 
disease outcome (39-41). In contrast, other groups demonstrated that Ki-67 does not provide 
additional information beyond what tumor stage and grade are already telling the 
pathologists/clinicians (20, 42). Thus, the prognostic value of Ki-67 immunostaining remains 
uncertain. 
 
Matrix metalloproteinases (MMP) and their inhibitors (tissue inhibitors of matrix 
metalloproteinases; TIMP) are thought to play an important role in tumor progression. Beside 
their well-known function in extracellular matrix organization newer studies have shown that 
MMPs and TIMPs also might have influence on cell proliferation, apoptosis, angiogenesis and 
immune response (43). Altered expression levels of individual MMPs and TIMPs have already 
been associated with disease progression in a variety of human tumors (44). Recently, increased 
TIMP1 expression was shown to be an independent (assessed in a multivariate analysis including 
tumor stage, grade and expression of other MMPs/TIMPs) predictor of shortened survival in 
cRCC (45). This finding is corroborated by other groups, which have linked increased TIMP1 
expression to shortened survival in colorectal, breast, and non-small cell lung cancer (46-48). By 
analyzing a subset of 153 archival, paraffin embedded primary cRCCs with patient follow-up 
data, we found that strong MMP3 immunopositivity is significantly associated with adverse 
outcome in advanced (pT3/pT4) tumors and that expression of TIMP3 protein is linked to 
occurance of lymphnode metastasis in this RCC subtype (own unpublished observations). 
Thus, altered expression levels of MMPs and TIMPs might be of importance for renal tumor 
biology and further studies in this field would be worthwhile. 
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The list of molecular markers tested for their value as prognostic parameters in RCC is endless. 
Although there are some promising candidates, tumor grade and stage are still the parameters of 
choice. 
 
1.6 Clear cell renal cell carcinoma (cRCC) 
 
As already mentioned in the previous sections, cRCC is the most common RCC subtype by far. 
Consequently, most previous studies have been done on cRCC and also the tissue material and 
cell lines used for the experiments in this thesis are stemming from cRCC. On this account, the 
histo- and molecularpathology of cRCC will be addressed in the following sections. 
 
1.6.1 Histopathology of cRCC 
 
As illustrated in figure 1, cRCCs arise from epithelial cells of the proximal tubulus (1). Prominent 
characteristics of cRCC are large plantcell-like cells with a clear cytoplasma due to the high 
contents of cholesterol, lipid, and glycogen which are eluted during routine processing of the 
tumor tissue (Figure 1). Clear cell RCCs generally show a solid growth pattern (28). Sarcomatoid 
differentiation and occurance of necrosis have been associated with adverse outcome (3). 
 
1.6.2 Cytogenetic and molecular alterations in cRCC 
 
First insights into the pathogenesis of RCC have been aquired using conventional cytogenetic 
analysis. Already in the late eighties and early nineties it could be demonstrated that loss of 3p 
sequences is fundamental to cRCC development occuring in up to 95% of the analyzed cases (49-
53).  
 
Introduction of Comparative Genomic Hybridization (CGH) analysis in 1992 facilitates the 
detection of DNA copy-number losses and gains in a given tissue sample (54, 55). To generate a 
CGH profile of a tumor, equal amounts of tumor and normal DNA are labelled with two different 
fluorochromes prior cohybridization to human metaphase chromosomes. The fluorescence 
intensity ratio of the two fluorochromes along the length of the chromosome is measured to 
calculate the DNA copy number changes within the tumor specimen. Many groups have studied  
Introduction 
Figure 1: Point of origin and histopathology of cRCC. 
(A) cRCC arise from the functional unit (nephron) of the kidney. Point of origin are epithelial cells of the 
proximal tubule (circle). cd = collecting duct; ct = collecting tubule; dt = distal tubule; gl = glomerulus; lh = 
loop of Henle; pt = proximal tubule. (B) H&E stained section of normal renal tissue with a schematic display 
of a cross section through the proximal tubule. ec = epithelial cell; pt = proximal tubule. (C) H&E stained 
section of cRCC showing the typical plantcell-like character of cRCC cells. (D) Cross section through kidney 
containing a cRCC. rc = renal cortex; rm = renal medulla; rp = renal pelvis; tu = tumor. 
 
cRCC using this technology and found that this RCC subtype is characterized by frequent losses 
of chromosomes 3p, 4q, 6q, 8p, 9p, 13q, 14q, and Xq and gains of 5q, 7, and 17 (56-58). Figure 2 
shows an example of a CGH profile of cRCC. Using CGH data, Jiang et al. (57) have constructed 
17 
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evolutionary trees for cRCC thereby gaining insight into the order of occurance of genetic 
alterations. Beside 3p, whose loss already was considered to be an early event in renal tumor 
biology (50, 59), they also found loss of 4q to be important in the initiation of cRCC. 
Additionally, due to their analysis, they suggested two distinct subclasses of cRCC from which 
one is characterized by successive loss of 13q, 9p, and 18q and the other one by successive loss 
of 6q, and gain of 17q and 17p. 
 
Certain cytogenetic alterations have already been implicated with progression of cRCC. For 
instance, loss of 9p, 13q, and 14q have been associated with shortened survival in advanced 
(Stage III and IV disease) cRCCs (56, 57, 60, 61). 
 
 
1 2 3 4 5 6 7 111098 12
13 14 15 16 17 18 19 20 21 22 Y X
 
 
 
 
 
 
 
 
 
 
 
 Figure 2: CGH profile of cRCC generated from 41 primary cRCCs (Moch et al. 1996). 
 
Bars on the right site of the chromosome: DNA sequence losses; bars on the left site of the chromosome: 
DNA sequence gains. 
 
 
Two important points can be summarized from the findings described above: 
 
(1) DNA sequence losses are much more frequent than DNA sequence gains suggesting that 
renal pathogenesis is mainly driven by loss of function of genes (potential tumor suppressor 
genes) located in these regions. 
18 
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(2) No amplified DNA sequences (harboring potential oncogenes) have been identified in 
primary cRCC. 
 
1.6.3 Molecular carcinogenesis of cRCC 
 
Obviously, loss of 3p sequences is the most common event in cRCC (50, 62, 63) indicating that 
genes localized in this chromosomal region are of particular importance for renal tumor biology. 
Interestingly, loss of 3p is also frequent in other solid human cancers, i. e. lung, breast, ovarian, 
and head and neck tumors (64-69). At least three separate regions of 3p, 3p25-26, 3p21-22, and 
3p12-14, are critical in the development of cRCC (62, 70-75). 
  
One of the first genes associated with sporadic cRCC was the Von Hippel-Lindau (VHL) gene, 
which is located at 3p25 and mutated in VHL syndrome (dominantly inherited familial cancer 
syndrome) families (76). Introduction of the VHL cDNA into renal cancer cell lines has 
functionally confirmed that this gene has tumor suppressive properties (77). Somatic mutations in 
all 3 exons and hypermethylation of the VHL promoter have been described in 34-85% (78-80) 
and 15-19% (80, 81) of the analyzed cRCCs indicating the importance of VHL in renal tumor 
biology. The VHL protein plays a role in the regulation of the cellular response towards hypoxia. 
Hypoxia activates the transcription factor HIF-α, which regulates expression of genes involved in 
angiogenesis, cell adhesion, extracellular matrix regulation, proliferation, and apoptosis 
(reviewed in (82-85). Under normal oxygen conditions, binding of VHL to HIF-α causes the 
ubiquitylation and degradation of HIF-α (86, 87). It has been shown that VHL inactivating 
mutations lead to stabilization of HIF-α in cRCC (86-88). According to this, HIF-α protein is 
abundant in primary cRCC in contrast to normal renal tissue (and other RCC subtypes) where 
HIF-α levels were very low or even undetectable (89, 90). Turner et al. could show that strong 
HIF-α expression is associated with increased vascular endothelial growth factor (VEGF) 
expression and microvessel density in cRCC (90). These findings indicate that impaired VHL 
function could promote cRCC development by constitutive activation of HIF-α, which leads to 
increased vascularization, paving the way for boundless tumorgrowth and metastasis. 
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Beside VHL, other genes located at 3p may be of importance for renal tumor biology. Dammann 
et al. (91) have identified a human RAS effector homologue (RASSF1), on 3p21.3, through its 
interaction with the human DNA repair protein XPA in a yeast 2-hybrid screen. Three splice 
variants of the RASSF1 gene (RASSF1A-C), of which RASSF1A seems to play a key role in 
tumorigenesis, are existing. Epigenetic silencing of the RASSF1A promotor has been described in 
24-91% of the analyzed primary cRCCs and in 100% of evaluated cRCC cell lines (92, 93). In 
contrast to VHL, which is strictly associated with cRCC, RASSF1A promoter methylation has also 
been obseved in pRCC (93). RASSF1A promoter methylation is also common in other human 
cancers, including breast, lung, prostate, ovarian, and skin tumors (94-98). Re-expression of 
RASSF1A resulted in growth suppression and reduced colony formation in a cRCC cell line 
corroborating the tumor suppressive function of this gene in renal pathogenesis (92). However, 
the mechanism by which RASSF1A contributes to renal tumorigenesis is yet unclear. The 
presence of a RAS association domain and a strong homolgy to Nore1 (a mouse RAS effector 
protein which in vivo interacts with Ras in a GTP-dependent manner following receptor 
activation (99)) suggest that RASSF1A functions in a Ras signalling pathway, possibly as a 
negative regulator of cell growth (91). 
 
By introducing a chromosomal fragment, encompassing 3p14-p12, into a highly malignant cRCC 
cell line Sanchez et al. (100) obtained dramatically reduced tumor growth in athymic nude mice 
suggesting another renal cancer relevant tumor suppressor gene on the short arm of chromosome 
3. In 1998, the region containing the tumor suppressor gene(s) was confined to 3p12 and 
designated nonpapillary renal carcinoma-1 (NRC-1) locus (101). Introduction of NRC-1 locus 
into different renal cancer cell lines showed that the tumor suppressive properties of 3p12 are 
independent of histological phenotype and VHL mutation status (102). The tumor suppressor 
gene(s) located at 3p12 remain to be identified. 
 
1.7 cDNA and tissue microarray technologies for the identification of cRCC relevant 
genes 
 
Because cancer is a multistep process it is unlikely that alterations of genes located at 3p are 
sufficient to induce and promote renal carcinogenesis. By CGH analysis it has been shown that 
virtually all chromosomes are affected in cRCCs (56-58) strongly suggesting that many more 
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genes are playing a role in renal tumor biology. Further studies are necessary to identify renal 
tumor relevant genes and evolve the molecular pathways leading to renal cancer initiation and 
progression. Those genes could than be used as diagnostic and prognostic parameters or as new 
targets for innovative and effective therapies. 
 
Recently, cDNA array technology was developed which allows expression analysis of thousands 
of genes in parallel thus accelerating and facilitating target gene identification. This technology 
offers the possibility to generate gene-expression profiles of each tissue of interest in a very short 
time enabling to uncover the molecularbiological processes leading not only to cancer but also to 
other diseases (103, 104). In cancer research, cDNA arrays have been employed to elucidate the 
molecular pathogenesis of tumor diseases (105-107), to promote the molecular subclassification 
of pathohistologically similar tumor entities (108, 109), to identify new diagnostic and prognostic 
markers and therapeutical targets (110-112), and to evaluate the response of tumor cells to 
different chemotherapeutical drugs (113, 114). 
 
Interpreting the multiparametric data, validating results, and prioritizing the candidate markers 
are the major challenges for microarray-based cancer profiling efforts. To assess the clinical 
significance of prognostic or diagnostic marker genes, large numbers of tissue samples have to be 
analyzed. This is rather cumbersome and time-consuming if large conventional histological 
sections are used. Recently, tissue microarrays (TMA) have been designed to analyze 
simultanously new cancer related genes in hundreds of tumors on the DNA, RNA, and protein 
level (115, 116). Consequently, a combination of cDNA microarray and TMA technology is 
particularly suitable for rapid identification and subsequent validation of potential novel cancer 
markers and prognostic parameters (117-120). 
 
1.8 Aim of the thesis 
 
Despite many efforts, the genetical background of renal carcinogenesis largely remains unclear. 
As a result of this, there is a lack of diagnostic and prognostic markers allowing reliable 
prediction of the clinical course of a renal tumor. Furthermore, there are virtually no therapeutical 
options for advanced renal cancer. Consequently, this tumor entity is still a challenge for 
pathologists and oncologists and the identification of genes with impact on renal tumor biology is 
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of great importance. Recently developed microarray technologies, like cDNA and tissue 
microarrays, allow rapid identification and validation of potentially tumor relevant genes.  
 
The aims of this thesis were to 
 
• uncover yet unknown cRCC associated genes (first part of this thesis) 
• further characterize a selected candidate gene (second part of this thesis) 
 
First part: High-throughput technologies for identification of differentially expressed genes. 
 
• Identification of potentially renal tumor relevant genes by comparing gene expression profiles 
of cRCC cell lines and normal renal tissue with each other using cDNA microarrays. 
• Verification of significantly differentially expressed genes by oligo-based RNA in situ 
hybridization (RISH) on tissue microarrays constructed from 61 fresh frozen primary RCCs 
and 12 normal renal tissues. 
 
Second part: Further studies on the highly differentially expressed gene BTG2 to assess its role 
in cRCC biology. 
 
• Confirmation of results from precedent cDNA and tissue microarray experiments using 
Northern blot analysis and quantitative RT-PCR on the LightCycler instrument (Roche). 
 
• Gain insight in the regulation of BTG2 gene transcription in renal cancer by analyzing BTG2 
mRNA expression levels in cRCC cell lines under certain conditions (TPA treatment, 
increasing cell density) with the help of quantitative RT-PCR. 
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2 Material and Methods 
 
2.1 Cell culture 
 
Human cRCC cell lines (Caki-1, Caki-2, 786-O, and 769-P) and the human cervix carcinoma cell 
line HeLa were obtained from American Type Culture Collection (ATCC). Caki-2, 786-O, and 
769-P cells derive from different primary cRCCs whereas Caki-1 was established from a skin 
metastasis of a cRCC. All cell lines were cultured in Optimem medium (Gibco) which was 
supplemented with 10% foetal calf serum (Amimed) and Penicillin/Streptomycin (100 IU/ml and 
100 µg/ml, respectively; Amimed). Medium renewal was done three times per week.  
 
Cells were detached using Trypsin-EDTA (0.05% Trypsin/0.02% EDTA; Amimed) following 
standard protocols (121). In order to store cells, cultures were detached and resuspended in 2-5 
ml culture medium. Cells were pelleted by centrifugation at 1000 rpm for 10 min at 4°C. Pellets 
were resuspended in culture medium containing 10% DMSO (Sigma) to a concentration of 1 x 
106 cells per ml and stored at –75°C. 
 
For cell counting, cells were stained with one volume trypan blue (Appendix) to visualize 
apoptotic cells and counted using a hemocytometer (Neubauer chamber), according to standard 
protocols (121). 
 
2.2 RNA extraction 
 
Extraction of total RNA from cell lines 
 
To extract RNA for cDNA array experiments, cells were quickly thawed at 37°C and pelleted at 
1000 rpm for 10 min at 4°C prior addition of TRIzol® reagent (Invitrogen). For Northern blot and 
quantitative RT-PCR experiments cells were detached by directly adding TRIzol® reagent 
(Invitrogen) to the culture vessel.  
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Total RNA was extracted according to the instructions given in the TRIzol® reagent manual 
(http://www.invitrogen.com/content/sfs/manuals/15596026.pdf). To eliminate contaminating 
DNA, RNA was treated using the DNAse I system of Qiagen. 
 
Extraction of total RNA from human lymphocytes 
 
Lymphocytes were isolated from human whole blood of healthy donors using Histopaque-1077 
(Sigma). In brief, whole blood (20-30 ml) was carefully pipetted onto one volume of Histopaque-
1077 and centrifuged at 1600 rpm for 10 min at room temperature to separate the lymphocytes 
from the erythrocytes. After centrifugation the lymphocyte-containing interphase was transferred 
into a 50 ml Falcon tube. Lymphocytes were washed with 20-30 ml PBS (Gibco). Cells were 
pelleted by centrifugation at 1600 rpm for 10 min at room-temperature. The pellet was 
resuspended in 2 ml TRIzol® reagent (Invitrogen) and total RNA was extracted as described 
above. 
 
Extraction of total RNA from snap-frozen tissues 
 
H&E stained histological sections (122) were prepared from each tissue prior RNA extraction. 
Representative tissue areas, identified on the H&E stained histological sections, were used for 
RNA extraction. One ml TRIzol® reagent (Invitrogen) was added to 15-20 frozen sections (each 
20-30 µm) of each sample and total RNA was extracted as described above. 
 
Extraction of polyA+ mRNA 
 
PolyA+ mRNA was extracted from total RNA using the polyA+ mRNA extraction kit of Qiagen 
according to the instructions of the manufacturer.  
 
Evaluation of RNA quantity and quality 
 
Total RNA concentrations were determined using a spectrophotometer (Genequant). To assess 
quality of total RNA, 0.5–1 µg was separated under denaturating conditions using 
agarose/formaldehyd gels as described in section 2.6. 
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2.3 cDNA array experiments 
 
Generation of cDNA array probes 
 
For each experiment, 5 µg of total RNA from cRCC cell lines Caki-1, Caki-2, 786-O, and 769-P 
and normal renal tissue (Invitrogen) were reverse transcribed and thereby labeled with (α-
32P)dATP (Amersham Pharmacia) using the AtlasTM Pure Total RNA Labeling System (BD 
Clontech). Unincorporated nucleotides were removed using the QIAquick Nucleotide Removal 
Kit according to the instructions of the manufacturer (Qiagen). 
 
cDNA array hybridization 
 
AtlasTM Human Cancer 1.2 cDNA Arrays (BD Clontech) were used for cDNA array analysis. 
These arrays contain cDNA spots of 1176 genes known to have impact on initiation and 
progression of human cancers.  
Prehybridization, hybridization, and washing of the cDNA microarrays was done according to the 
recommendations of the manufacturer. After hybridization, arrays were exposed to high 
resolution Phosporimager screens (Packard) for 24 h and scanned using the Cyclone 
Phosphorimager (Packard). 
 
Evaluation of cDNA array data 
 
AtlasImage software 1.01a (BD Clontech) was used for digital image analysis. Background 
corrected signal density (sDens) values were calculated for each arrayed spot and were 
normalized according to the AtlasImage sum method. Only those spots showing sDens values ≥ 
4500 were clearly distinguishable from background noise. Therefore, spots with sDens values < 
4500 were excluded from analysis.  
 
sDens ratios were calculated between each cRCC cell line showing gene expression (sDens ≥ 
4500) and normal renal tissue. We also included genes in our analysis, which were not expressed 
in normal renal tissue (sDens < 4500) but which were strongly expressed (sDens ≥ 13500; 3x 
threshold value) in at least two cell lines (and vice versa). In those cases sDens ratios were 
calculated as described above. 
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Genes showing expression alterations > 0.5-fold and < 2-fold were considered to be equally 
expressed. Expression alterations ≤ 0.5-fold and ≥ 2-fold in at least two cell lines were defined as 
decreased or increased, respectively, in cRCC cell lines compared to normal renal tissue.  
Only genes with expression alterations ≤ 0.25-fold and ≥ 4-fold in at least two cell lines were 
further studied by RISH on renal TMAs.  
 
2.4 RNA in situ hybridization on frozen renal tissue microarrays 
 
TMA construction 
 
Sixty-one renal cancer samples and 12 normal renal tissues were used for TMA construction. All 
tissue samples derived from the tumorbank of the Institute of Pathology in Basel. Renal tumor 
subtypes were defined according to Thoenes et al. (1). Histological grade and the pT category of 
the tumors were determined according to Thoenes and recommendations of the UICC, 
respectively (1, 29). Table 3 shows an overview of the renal tissues arrayed on the frozen TMA. 
 
Table 3: Composition of renal TMA. 
 
  pT category grade   
tissue1  n 1 2 3 ni2 1 2 3 ni2
cRCC 51 32 4 15 - 12 30 7 2 
pRCC 4 1 - 3 - 2 2 - - 
chRCC 4 1 3 - - 1 2 - 1 
oncocytoma 2 1 - - 1 - - 1 1 
normal kidney 12 - - - - - - - - 
1 cRCC = clear cell RCC; pRCC = papillary RCC; chRCC = chromophobe RCC 
2 ni = no information available 
 
Conventional H&E stained histological sections were prepared from each tissue (122). All 
sections were reviewed by a pathologist to select representative tissue areas which were than used 
for TMA construction. Tissue microarray construction was largely done according to Schoenberg 
et al. (116). At our laboratory, frozen TMA manufacturing was optimized by using a drill (0.6 
mm diameter) instead of a hollow needle to bore wholes into the recipient block. Figure 3 briefly 
illustrates the construction of a TMA. Conventional H&E stainings (122) were made from the 
TMA sections to ensure integrity of every single tissue spot. Generated TMA blocks as well as 
TMA sections were stored at –75°C. 
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Figure 3: Construction of frozen TMA. 
 
(A) Front view of the tissue arrayer. 1 = receptacle for the recipient (array) block; 2 = donor block bridge; 3 =
turret for switching needle/drill between donor and recipient block. (B) Piece of frozen tissue placed on 
Tissue-Tek (arrow) to facilitate sectioning and handling. H&E stained sections were prepared to assign
representative tissue areas. (C-H) Individual TMA production steps: (C) recipient block is fixed in the
receptacle and permanently cooled with dry-ice; (D) drilling of the recipient whole; (E) retrieving the tissue
sample using a hollow needle; (F) tissue core biopsy is cooled with dry-ice; (G-H) tissue is transferred into 
the pre-made whole of the recipient block. 
 
Design of antisense oligonucleotide probes 
 
For each gene to be analyzed by RISH 2-4 oligonucleotides were designed using the Vector NTI 
software package (InforMax Inc., Frederick, MD, USA). All oligonucleotides consisted of 35 to 
55 nucleotides, had a guanosine-cytosine content of 50 to 60%, and had no palindromic 
sequences. Specificity of the probes was confirmed using the BLAST® program 
(http//www.ncbi.nlm.nih.gov). Oligonucleotide sequences showing more than 25 successive 
nucleotides that were homologous to any other gene than the target gene were discarded.  
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Labelling of oligonucleotide probes 
 
Oligonucleotides were labeled separately with (α-33P)dATP (Amersham Pharmacia) using 
terminal deoxynucleotidyl transferase (TdT; Promega). Twenty ng oligonucleotide were 
combined with 1 µl nuclease free water, 1 µl 5 X TdT buffer (500 mM cacodylate buffer, pH 6.8; 
5 mM CoCl2; 0.5 mM DTT), 20 µCi (α-33P)dATP, and 1 µl TdT (15-30 units). The reaction was 
performed at 37°C for 2 h. After labelling, oligonucleotides concerning to one gene were pooled. 
Unincorporated nucleotides were removed using the QIAquick nucleotide removal (Qiagen). The 
activity of the radiolabeled probes was determined by pipetting 1 µl of the purified probe into 10 
ml of Ultima Gold MV solution (Packard). The mixture was transferred into a liquid scintillation 
counter. Probes suitable for RISH had an activity of at least 1 x 108 counts per minute (cpm) per 
ml. 
 
RISH 
 
Radiolabeled probes (activity ≥ 108 cpm/ml) were combined with 6 µl DTT (5 M) and RISH 
hybridization mix (Appendix) to a total volume of 200 µl. The mixture was vortexed and 
incubated at 42°C for 1 h prior addition of 10 µg heat-denatured Human Cot-1 DNA. After 
adding the hybridization mixtures, the TMA sections were covered with a spacer-coverslip and 
incubated in a moist chamber at 42°C for 36 h. After hybridization, slides were washed in 1 X 
SSC (prepared from 20 X SSC stock solution, see Appendix) at 55°C for 15 min (4 times), in 1 X 
SSC at room temperature for 1 h, and in distilled water at room temperature for 30 s. Afterwards, 
slides were dehydrated in 60% and 90% ethanol (30 s each) and air-dried. The dried slides were 
exposed to high resolution Phosphorimager screens (Packard) for 48 h prior scanning using a 
Cyclone Phosphorimager (Packard). 
 
Image analysis 
 
ArrayVision software (Imaging Research Inc., St. Catharines, Ontario, Canada) was employed to 
measure signal density (sDens) values of the array spots. To address possible heterogeneity of a 
given tissue spot, signal densities were measured over the whole area of each spot. The mean 
value from these sDens values (mean sDens) was than calculated for every single tissue spot. 
RCC and normal renal tissue spots were considered positive for gene expression if the mean 
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sDens was at least twice as high as the mean background sDens of the TMA section. The other 
spots were considered negative for gene expression. 
 
Specificity of RISH was evaluated by direct autoradiograpy of the TMA slide using HypercoatTM 
LM-1 emulsion (Amersham Pharmacia) according to the instructions of the manufacturer. After 
development of the emulsion, slides were counterstained with Harris‘ hematoxylin (122) and 
were analyzed under a conventional light microscope to identify those spots, which were 
completely or partly lost during the sectioning, hybridization, and washing process. Only spots 
containing more than 60% tumor or normal tissue, respectively, cells were included in further 
statistical analysis.  
 
Statistical evaluation of RISH results 
 
Only primary cRCCs and normal renal tissues were included in statistical analysis since the 
numbers of the other RCC subtypes on the TMA were to low. All statistical analysis were done 
using StatView 5.0.1 software package (SAS institue Inc.) RISH results were evaluated for each 
analyzed gene in two ways: 
 
(1) Expression frequency. Contingency table (Chi Square) analysis was performend to search 
for differences in the percentage of tissue spots positive for gene expression (mean sDens ≥ 2-
fold background sDens) between normal renal tissue and cRCC and also within the subset of 
cRCC. 
 
(2) Expression level. Anova analysis was applied to compare gene expression levels (mean 
sDens values) of spots with positive gene expression between normal renal tissue and cRCC 
and also within the subset of cRCC. 
 
2.5 Cloning of BTG2 and G3PDH sequences 
 
BTG2 and G3PDH sequences were cloned for two purposes: 
 
• Generation of single stranded DNA probes for Northern analysis (section 2.6). 
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• Generation of in vitro transcribed RNA to establish standard curves for quantitative RT-PCR 
(section 2.7.2). 
 
The pGEM®-T Easy Vector system (Promega), which is especially suited to clone PCR products 
and which contains SP6 and T7 RNA polymerase promoter sequences, was used. 
 
Generation of inserts by PCR 
 
BTG2 and G3PDH PCR products of about 1 kb were generated from reverse transcribed human 
lymphocyte RNA using 2.5 µl of AmpliTaq® Gold 10 X PCR buffer (1.5 mM Tris-HCl, pH 8.0; 
and 500 mM KCl), 0.2 mM dATP, dCTP, dGTP, and dTTP (Invitrogen), sequence-specific 
primer pairs for BTG2 (forward: 5'-AGG GTA ACG CTG TCT TGT GG-3' and reverse: 5'-CAG 
GAG AGG CCT TTT CAC TC-3') and G3PDH (forward: 5'-ACA GTC AGC CGC ATC TTC 
TT-3' and reverse: 5'-AGG GGA GAT TCA GTG TGG TG-3') at a final concentration of 0.5 µM 
each, and 0.25 units of AmpliTaq® Gold polymerase (Applied Biosystems) in a total volume of 
25 µl. Amplification was done for 10 min at 95°C, 35 cycles with 30 s at 95°C, 30 s at 58°C, and 
1 min at 72°C. Subsequent incubation of the PCR reaction at 72°C for 10 min ensured sufficient 
generation of 3‘-Adenosin overhangs. PCR products were cleaned-up using the Quiaquick PCR 
purification kit (Quiagen). PCR products bound to the Quiaquick columns were eluted in 30 µl 
elution buffer, which was supplied in the kit.  
 
Cloning and selection 
 
Two µl of the purified PCR product were combined with 5 µl Rapid Ligation Buffer, 50 ng 
pGEM®-T Easy Vector DNA, 3 units T4 Ligase, and deionized water to a final volume of 10 µl. 
The reaction was incubated overnight at 4°C. Two µl of each ligation reaction were carefully 
mixed with 50 µl of JM109 High Efficiency Competent Cells (supplied with the pGEM®-T Easy 
Vector kit). The mixture was placed on ice for 20 min prior heat-shock at 42°C for exactly 50 s. 
Transformed cells were immediatly returned to ice for another 2 min. 
 
Transformed cultures were mixed with 950 µl LB medium (Appendix) and incubated for 90 min 
at 37°C with shaking. One hundred µl of each culture were plated on LB/Agar plates 
supplemented with X-Gal and IPTG (Appendix). Plates were incubated at 37°C overnight. 
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Confirmation of cloned inserts 
 
White colonies (containing the insert) were picked and transferred into microtiterplates 
containing 150 µl LB (Appendix) medium per well. Plates were incubated at 37°C for 2-3 h. PCR 
was done to confirm cloned inserts. In brief, 2-5 µl from each well of the microtiterplate was 
amplified using 2.5 µl of AmpliTaq® Gold 10 X PCR buffer (1.5 mM Tris-HCl, pH 8.0; 500 mM 
KCl), 0.2 mM dATP, dCTP, dGTP, and dTTP (Invitrogen), primers specific for SP6 (forward: 5'-
GCC AAG CTA TTT AGG TGA CAC T-3') and T7 (reverse: 5'-ACG GCC AGT GAA TTG 
TAA TAC G-3') at a final concentration of 0.5 µM each, and 1.25 units of AmpliTaq® Gold  
polymerase (Roche) in a total volume of 25 µl for 10 min at 95°C and 35 cycles with 30 s at 
95°C, 30 s at 60°C, and 1 min at 72°C. Five µl of each PCR product were analyzed by gel 
electrophoresis. 
 
Gel electrophoresis 
 
DNA was separated on conventional 1.2% agarose (Invitrogen) gels using 1 X TAE (prepared 
from 50 X TAE stock solution, see Appendix) as a running buffer (123). DNA molecular weight 
marker III (Roche) and a 100 bp-ladder (Invitrogen) were used as size standards. 
 
Extraction of Plasmid DNA (Miniprep) 
 
Twenty µl of each clone containing the appropiate insert were transferred into 5 ml LB medium 
(Appendix) and incubated at 37°C for 12-16 h. Plasmid-DNA was extracted using the QIAprep 
spin plasmid kit (Qiagen). Amount of plasmid DNA was assessed using a spectrophotometer 
(Genequant). 
 
Sequencing 
 
Direction of the cloned insert was determined by sequencing using the ABI 310 Prism sequencer 
(Applied Biosystems). PCR products were generated from 50 ng of each plasmid DNA according 
to the protocol described above (Confirmation of cloned insert). PCR products were purified 
using the Quiaquick PCR purification kit (Qiagen). PCR products bound to Quiaquick column 
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were eluted in 50 µl elution buffer supplied with the kit. Two µl of this eluate were combined 
with 8 µl BigDye Terminator v 2.0 (BigDye Terminator Cycle Sequencing v 2.0 kit; Applied 
Biosystems), SP6 sequencing primer (5'-ATT TAG GTG ACA CTA TAG AA-3') at a final 
concentration of 0.5 µM, and PCR grade water to a total volume of 20 µl. The reaction was 
incubated for 25 cycles with 96°C for 20 s, 50°C for 10 s, and 60°C for 4 min. Reaction products 
were pelleted by addition of 2.5 volumes of 100% ethanol and 1/10 volume of 3 M sodiumacetate 
(pH5.2) and incubation at –20°C overnight prior centrifugation at 14000 rpm for 30 min at 4°C. 
The pellet was washed in 75% ethanol and dried prior addition of 14 µl Template Suppression 
Reagent (Applied Biosystems). Before sequence analysis, the product was denatured at 95°C for 
10 min and chilled on ice. 
 
2.6 Northern blot analysis 
 
Gel electrophoresis of RNA 
 
RNA was separated under denaturing conditions using agarose/formaldehyde gels and 1 X 
MOPS (prepared from 10 X MOPS stock solution, see Appendix) as a running buffer (123). RNA 
MilleniumTM Size Marker (Ambion) and the RNA Marker from Promega were used as size 
standards. 
 
Blotting 
 
Gels were rinsed in RNAse free water to remove formaldehyde prior blotting to HybondTM-N+ 
membranes (Amersham) using the capillary transfer method and 20 X SSC (Appendix) as a 
transfer buffer (123). To immobilize RNA, the membranes were incubated at 80°C for 1.5-2 h. 
RNA was visualized by incubating the membrane in methylene-blue staining solution (Appendix) 
for 30-60 s. The membrane was rinsed in RNAse free water to remove excess staining solution 
and airdried. 
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Northern analysis using (α-32P)dATP labelled single-stranded DNA probes 
 
To verify the results obtained for BTG2 by cDNA microarray experiments (α-32P)dATP labelled 
single-stranded DNA probes were hybridized to poly A+ mRNA of cRCC cell lines, normal renal 
tissue, and human lymphocytes (positive control).  
 
To generate sequence-specific probes for BTG2 and G3PDH (reference), 50 ng plasmid DNA 
(preperation described in section 2.5) containing the cloned insert of BTG2 or G3PDH, 
respectively, were amplified as described in section 2.5 (Confirmation of cloned inserts). PCR 
products were purified using the Qiaquick PCR purification kit (Qiagen).  
 
For labeling, 25ng BTG2 and G3PDH PCR product were combined with 25 ng BTG2 reverse 
primer (5'-CAG GAG AGG CCT TTT CAC TC-3') or 25 ng G3PDH reverse primer (5'-AGG 
GGA GAT TCA GTG TGG TG-3'), respectively, denatured at 100°C for 10 min, and chilled on 
ice. Labelling reaction was performed in a total volume of 25 µl containing 2.5 µl 10 X Klenow 
Fragment buffer (500 mM Tris-HCl, pH7.2; 100 mM MgSO4; 1 mM DTT), 0.5 M dCTP, dGTP, 
and dTTP (Invitrogen), 50 µCi (α-32P)dATP (Amersham Pharmacia), and 5 units Klenow 
Fragment (Promega) for 1 h at 25°C. Reaction was stopped by adding 1 µl 0.5 M EDTA (pH8.0). 
QIAquick nucleotide removal kit was applied to remove unincorporated nucleotides (Qiagen). 
 
Single-stranded DNA probes were hybridized to polyA+ mRNA, which was extracted from 30 µg 
total RNA of each cRCC cell line (Caki-1, Caki-2, 786-O, and 769-P), normal renal tissue 
(Invitrogen), and human lymphocytes, respectively. Prehybridization and hybridization of the 
membrane was done at 42°C in formamide prehybridization/hybridization (FPH) solution 
(Appendix). To block unspecific binding of the probe, prehybridization was done with heat-
denatured salmon sperm DNA (100 µg/ml FPH solution; Sigma) for 1 h prior addition of heat 
denatured BTG2 and G3PDH probes. Hybridization was done overnight. Washing was done 
twice at 42°C in wash solution I (Appendix) for 15 min, twice at 42°C in wash solution II 
(Appendix) for 10 min, and also twice at 68°C in wash solution III (Appendix) for 5 min. The 
membrane was exposed to a high resolution Phosphorimager screen (Packard) for 6-12 h prior 
scanning using the Cyclone Phosphorimager (Packard). 
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Northern hybridization using (α-32P)dATP labelled oligonucleotide probes 
 
To verify the specificity of the BTG2 oligonucleotides used in the RISH experiment, (α-
32P)dATP labelled oligonucleotides were hybridized to total RNA from human lymphocytes. In 
brief, BTG2 oligonucleotide probes were generated and purified as described in section 2.4 
(Labelling of oligonucleotide probes) with the exception that (α-32P)dATP was used for labelling 
instead of (α-33P)dATP. 
 
BTG2 oligonucleotide probes were hybridized to 10 µg total RNA from human lymphocytes. 
Prehybridization and hybridization of the membrane was done as described in section 2.4 (RISH 
on TMA) with the exception that hybridization was done overnight only and the washing step in 1 
X SCC at room temperature was reduced to 15 min. For signal detection, the membrane was 
exposed to a high resolution Phosphorimager screen (Packard) for 12 h prior scanning using the 
Cyclone Phosphorimager (Packard). 
 
2.7 Quantification of BTG2 mRNA copy numbers using the LightCycler 
 
2.7.1 General aspects of quantitative PCR using the LightCycler system 
 
Each PCR starts with a background phase followed by an exponential (or log) phase and ends in a 
plateau phase. By using the fluorochrome SYBR green, which binds to double stranded DNA, the 
increase of PCR product during an amplification reaction can be detected by the LightCycler 
system (figure 4). 
 
During amplification, the number PCR products present at a certain PCR cycle is described by 
the equation: 
Nn = N0 x En 
Where Nn is number of products at PCR cycle n; N0 is initial number of product (template); E is amplification 
efficiency; n is number of PCR cycle 
 
Accurate DNA quantification is only possible in the log-phase of a PCR in which E is constant. 
In theory, the maximal amplification efficiency in log-phase is 2 so that every PCR product is 
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replicated once per cycle. In practice amplification efficiencies in this phase are generally less 
than 2 due to many factors that could inhibit PCR reactions (suboptimal primers, PCR inhibitors 
in sample material etc.).  
2 0 2 1 2 2 2 3
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igure 4: DNA amplification profile. 
Increasing SYBR green emission is detected by the LightCycler system. 
 
To determine amplification efficiencies for individual PCRs, serial template dilutions have to be 
amplified on the LightCycler instrument. Standard curves and their slopes are determined using 
the software provided by the LightCycler system. Amplification efficiencies are described by the 
equation: 
 
E = 10 –1/-slope
Where E is amplification efficiency; slope is slope of standard curve. 
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The easiest way to determine absolute mRNA copy numbers of a gene of interest is to use an 
external standard, which is prepared from serial dilutions of in vitro transcribed RNA with known 
concentrations. Standard curves can be generated by reverse transcription of this dilution series in 
a separate reaction followed by amplification of the obtained first strand cDNA products on the 
LightCycler system (two-step RT-PCR). Based on these standard curves, concentrations of a 
target sample can be determined. However, quantification of mRNA copy numbers using this 
method do not necessarily reflect the actual and physiological expression level of a gene since 
Material and Methods 
36 
faulty processing and storage of sample material as well as irregularities in extraction and 
improper storage of RNA might affect the abundance of a transcript. For these reasons, it makes 
sense to determine mRNA expression level of a gene of interest relative to a 
housekeeping/reference gene to adjust for alterations in mRNA copy numbers induced by 
experimental treatment. If this approach is used, separate standard curves have to be generated to 
determine the mRNA concentrations of the gene of interest and the reference gene in a given 
sample. 
 
Guidelines for preparation of standard curves are (according to Roche): 
 
• Standard sequences should differ only slightly by lenght and/or sequence from the target 
sequences so that amplification with the same pair of primers is possible. 
• Size of the PCR products amplified from the gene of interest and the reference gene should be 
as similar as possible 
• Amplification efficiency of gene of interest and reference gene should differ by no more than 
± 0.05. 
• At least 5 points for creation of a standard curve should be used, which should cover the 
expected concentration range of the gene of interest and the reference gene 
 
2.7.2 Generation of standard curves from BTG2 and G3PDH in vitro transcripts 
 
Generation of plus strand RNA (in vitro transcription) 
 
From both plasmids generated in section 2.5 plus strand run-off in vitro transcripts were 
synthesized. Therefore, the circular plasmid DNA had to be linearized using Pst I and Sph I 
restriction enzymes. As illustrated in figure 5, Pst I recognizes the site CTGCA↓G and cuts 
between the SP6 promoter and the insert whereas Sph I recognizes the site GCATG↓C and cuts 
between the T7 promoter and the insert.  
 
Linearization of each plasmid DNA was done according to the instructions of the manufacturer of 
the restriction enzymes (Promega). Reactions were incubated at the appropriate temperatures for  
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Figure 5: Restrictionsites of the pGEM®-T Easy Vector.  
Restrictionsites for Pst I and Sph I are indicated by arrows. 
 
4 h. To ensure completeness of the digestion, linearized DNA was analyzed by conventional gel 
electrophoresis as described in section 2.5. 
 
In vitro transcription was done using the Riboprobe® in vitro Transcription System from 
Promega. Two µg linearized plasmid DNA were mixed with 20 µl Transcription Optimized 5 X 
Buffer, 10 µl DTT (100 mM), 29 µl nuclease free water, 2.5 µl RNAsin (40 units/µl), and 2.5 µl 
Klenow Fragment (5 units/µl; Promega) and incubated for 20 min at 22°C. This step converts the 
sticky ends, produced by Pst I and Sph I, into blunt ends thus avoiding initiation of transcription 
from the terminus of the template. After this step, 20 µl rNTP-Mix (2.5 mM of rATP, rCTP, 
rGTP, and rUTP), and 2.6 µl SP6 or T7 polymerase (10-20 units/µl) were added and the mixture 
was incubated at 30°C for 2 h. After in vitro transcription, plasmid DNA was degraded by 
addition of 2 µl RQ1 RNAse-free DNAse (1 unit/µl). RNA was purified using the RNeasy kit 
from Qiagen. Quality of in vitro transcripts was assessed using agarose/formaldehyde gels as 
described in section 2.6. Amount of in vitro transcripts was determined using a 
spectrophotometer (Genequant). 
 
Generation of serial dilutions with known concentrations 
 
The molecular weights (MG) of BTG2 and G3PDH in vitro transcripts were calculated as 
recommended by Ambion (http://www.ambion.com):  
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MG (g/mol) = (An x 328.2) + (Un x 305.2) + (Cn x 304.2) + (Gn x 344.2) + 159 
Whereas n is the number of nucleotide within the RNA sequence. 
 
The copy number (n) was determined by: 
 
concentration of in vitro transcript (g/l) * 6.02 x 1023 mol-1
MG of in vitro transcript (g/mol)
n = 
 
Whereas n is in vitro transcript copy number, 6.02 x 1023 mol-1 is the constant of Avogadro, and MG is the molecular 
weight. 
 
Serial dilutions of BTG2 and G3PDH in vitro generated transcripts were mixed with ribosomal 
RNA from mice (Roche) to a final concentration of 0.5 µg/µl of ribosomal RNA.  
 
Two-step RT-PCR 
 
Reverse transcription. Two µl of each in vitro generated transcript (containing 1 µg of 
ribosomal RNA and the corresponding copy numbers of the in vitro transcripts) were combined 
with nuclease free water to a total volume of 9.5 µl. After incubation at 65°C for 10 min, RNA 
was chilled on ice. Fifty ng random hexamers (Invitrogen), 1 mM of dATP, dCTP, dGTP, and 
dTTP (Invitrogen), 5 mM MgCl2, 1.5 mM Tris-HCl (pH 8.0), and 500 mM KCl, 100 units of M-
MLV reverse transcriptase (Invitrogen), and 20 units of RNAsin (Roche) were added to a total 
volume of 19.5 µl. The reaction was incubated at 25°C for 10 min and 37°C for 60 min. After 
heat inactivation of the enzymes the remaining RNA in the reaction mixture was degraded for 20 
min at 37°C with 0.5 µl (1 unit) of RNAse H (Invitrogen). A 1:2.5 dilution was prepared from 
each first strand cDNA synthesis product. 
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Quantitative PCR. Five µl of each first strand cDNA synthesis product generated above were 
combined with 2 µl of LightCycler-FastStart DNA Master SYBR Green I (Roche), primer-pairs 
for BTG2 (forward: 5'-CTC ACC TGC AAG AAC CAA GTG-3'; reverse: 5'-AGT TCC CCA 
GGT TGA GGT ATG T-3') or G3PDH (forward:5'-GAA ATC CCA TCA CCA TCT TCC-3'; 
reverse: 5'-CAG AGA TGA TGA CCC TTT TGG-3') at a final concentration of 1 µM each, and 
MgCl2 at a final concentration of 2 mM for BTG2 and 3 mM for G3PDH. Amplification was 
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performed in a total volume of 20 µl for 10 min at 95°C and 40 cycles with 15 s at 95°C, 10 s at 
58°C, and 7 s at 72°C.  
 
Amplification efficiencies (E) were calculated as described in section 2.7.1. Melting curve 
analysis (LightCycler software package) was applied to ensure the specificity of the PCR 
reaction.  
 
2.8 BTG2 mRNA expression in primary cRCC and normal renal tissue 
 
Tissue collective 
 
Forty-two primary cRCCs and 12 normal renal tissues taken from the tumorbank of the Institute 
of Pathology in Basel were analyzed by quantitative RT-PCR. Histological grade and pT 
category were determined according to Thoenes and recommendations of the UICC, respectively 
(1, 30). Eight cRCCs were grade 1, 28 grade 2, and 6 grade 3. There were 20 pT1, 7 pT2, and 15 
pT3 cRCC. 
 
Quantification of BTG2 expression 
 
To determine BTG2/G3PDH mRNA copy numbers, RT-PCR was done from 1 µg total RNA of 
each sample exactly following the protocol described in section 2.7.2 (Two-step RT-PCR). 
 
Statistical analysis 
 
All statistical analysis were done using StatView 5.0.1 software package (SAS institue Inc.). 
In a first step, Anova analysis was applied to search for differences in BTG2 and G3PDH mRNA 
copy numbers in cRCC and normal renal tissue.  
In a second step, BTG2 mRNA copy numbers were normalized to G3PDH mRNA copy numbers 
in each sample to correct for differences in the quality and quantity of RNA. Anova analysis was 
applied to search for differences in normalized BTG2 mRNA expression. The association of 
BTG2 mRNA expression with tumor grade and pT category was determined using Anova 
analysis. 
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2.9 Inducibility of BTG2 mRNA expression in cRCC cell lines 
 
Induction of BTG2 mRNA expression by 12-O-tetradecanoylphorbolester-13-acetate (TPA) 
 
cRCC cell lines Caki-1, Caki-2, 786-O, 769-P and the positive control cell line Hela were plated 
at 5 x 105 cells/25 cm2 culture vessel. Medium renewal was done 24 h after plating. RNA was 
extracted after 48 h from each cell line to determine the BTG2 mRNA expression levels prior 
TPA treatment. The remaining cells were treated with various concentrations of TPA (25 ng, 50 
ng, 75 ng, or 100 ng per ml culture medium, respectively) or DMSO alone (0.1% final 
concentration) and incubated for 70 min prior RNA extraction. To determine BTG2/G3PDH 
mRNA copy numbers, RT-PCR was done from 1 µg total RNA of each sample exactly following 
the protocol described in section 2.7.2 (Two-step RT-PCR). 
 
BTG2 mRNA expression and cell density 
 
Caki-1, Caki-2, 786-O, 769-P and Hela were plated at 1 x105, 2 x 105, and 5 x 105 cells/well in 6-
well-plates. Medium renewal was done 24 h after plating. RNA was extracted after 48 h. At this 
time, cultures had - according to initial cell numbers - low, medium or high cell densities. To 
determine BTG2/G3PDH mRNA copy numbers, RT-PCR was done from 1 µg total RNA of each 
sample exactly following the protocol described in section 2.7.2 (Two-step RT-PCR). 
Results 
3 Results 
 
3.1 cDNA array analysis 
 
To identify renal tumor relevant genes, gene expression profiles of four cRCC cell lines (Caki-1, 
Caki-2, 786-O, and 769-P) and one normal renal tissue were compared with each other. For this 
purpose, AtlasTM Human Cancer 1.2 cDNA microarrays, containing 1176 cDNA spots, were 
used. Microarray spots with sDens values ≥ 4500 were regarded as positive for gene expression. 
According to this threshold, expression of 748 genes was not detectable in any of the analyzed 
samples (sDens value < 4500). sDens ratios were calculated for (i) genes which were expressed 
(sDens ≥ 4500) in normal renal tissue and cRCC cell line(s) and (ii) also for genes, which were 
not expressed (sDens < 4500) in normal renal tissue but strongly expressed (sDens ≥ 13500) in 
cRCC cell line(s) and vice versa. Genes with sDens ratios ≤ 0.5 and ≥ 2 in at least two cell lines 
were regarded as differentially expressed in cRCC cells compared to normal renal tissue. 
According to these definition, 36 genes were stronger expressed in at least two cRCC cell lines 
compared to normal renal tissue. Of those cases, expression of 18 genes was not detectable in 
normal renal tissue but was very strong in at least two cRCC cell lines (sDens value ≥ 13500). In 
contrast, 35 genes showed reduced expression levels in at least two cRCC cell lines. Fifteen of 
these genes were strongly expressed in normal renal tissue (sDens value ≥ 13500) but were 
undetectable in at least two cRCC cell lines.  
 
n = 748
n = 36
n = 62
n = 35
n = 295
not expressed 
increased expression 
equally expressed
reduced expression 
others
 
 
 
 
 
 
Figure 6: Overview of cDNA microarray hybridization results. 
 
The expression patterns of 1176 cancer related genes have been analyzed in 4 cRCC cell lines and one
normal renal tissue. not expressed = sDens < 4500 in all cRCC cell lines and normal renal tissue; increased
expression = sDens ratio ≥ 2 in at least two cRCC cell lines compared to normal renal tissue; equally
expressed = sDens ratio > 0.5 and < 2 in all cRCC cell lines and normal renal tissue; reduced expression =
sDens ratio ≤ 0.5 in at least two cRCC cell lines compared to normal renal tissue; others = genes showing
expression patterns different from those described above. 
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Sixty-two genes were equally expressed in normal renal tissue and in all cRCC cell lines because 
they had sDens ratios > 0.5 and < 2.The remaining 295 genes did not fit into any of the above 
mentioned categories. Figure 6 gives an overview of the results from the cDNA microarray 
experiments. Only genes, showing at least 4-fold expression level differences in at least two cell 
lines (Table 4) were regarded as significantly differentially expressed. Those genes were selected 
as candidate genes for further studies by RISH. As an example, cDNA microarray results 
obtained from normal renal tissue and the cell line 769-P as an representative for all other 
analyzed cRCC cell lines are shown in figure 7. 
 
Table 4: Candidate genes for further RISH experiments identified by cDNA array analysis. 
 
 
 
Position on 
cDNA 
microarray1
Gene name Abbreviation in text2
Chromosomal 
locus 
Gene bank 
accession 
number  
1 Centromeric protein F CENPF 1q32-q41 NM_016343 
2 CDC28 protein kinase regulatory subunit 1B CKS1B 8q21 NM_001826 
3 Chondroitin sulfate proteoglycan 2 CSPG2 5q12-q14 NM_004385 
4 Fibronectin 1 FN1 2q34 NM_002026 
5 FOS-like antigene 1 FOSL1 11q13 NM_005438 
6 High mobility group AT-hook 1 HMGA1 6p21 NM_002131 
7 Integrin alpha 3 ITGA3 17 NM_002204 
8 Integrin beta 8 ITGB8 7p15.3 NM_002214 
9 Tubulin alpha ubiquitous K-alpha-1 12q13.11 NM_006082 
10 Plasminogen activator inhibitor type 1 PAI1 7q21.3-q22 NM_000602 
11 Transforming growth factor beta induced TGFB1 19q13.1 NM_000358 in
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12 Vimentin VIM 10p13 NM_003380 
13 Basigin BSG 19p13.3 NM_001728 
14 B-cell translocation gene 2 BTG2 1q32 NM_006763 
15 CD74 antigen CD74 5q32 NM_004355 
16 CD9 antigen CD9 12p13 NM_001769 
17 Checkpoint supppressor 1 CHES1 14q24.3-q31 NM_005197 
18 Cathepsin D CTSD 11p15.5 NM_001909 
19 Early growth response 1 EGR1 5q31.1 NM_001964 
20 FC fragment of IgG, receptor transporter, alpha FCGRT 19q13.3 NM_004107 
21 growth arrest-specific 6 GAS6 13q34 NM_000820 
22 Integrin alpha 6 ITGA6 2q31.1 NM_000210 
23 LPS-induced TNF alpha factor LITAF 16p13.3-p12 NM_004862 
24 nuclear hormone receptor NR0B2 1p36.1 NM_021969 
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25 Tissue inhibitor of matrixmetalloproteinases 3 TIMP3 22q22.1-q13.2 NM_000362 
1 See figure 7. 
2 Abbreviation for gene name used in the text. 
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igure 7: cDNA microarray hybridization of normal renal tissue and cRCC cell line 769-P. 
 
 
3.2 RNA in situ hybridization 
 
Twenty-five significantly differentially expressed genes (Table 4) identified by preceding cDNA 
microarray experiments were further studied by oligo-based RISH on primary RCCs to assess 
their impact on renal tumor biology. 
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The renal TMA 
 
To study the expression patterns of the selected candidate genes by RISH, TMAs were generated 
from 61 snap-frozen primary RCCs and 12 normal renal tissues (Figure 8).  
1 cm 
Figure 8: The frozen renal TMA. 
 
(A) The frozen renal TMA composed of 73 different renal tissue core biopsies. (B) Localization and number 
of different RCC subtypes arranged in the renal TMA. There are 51 cRCCs, 4 pRCCs, 4 chRCCs, 2
oncocytomas and 12 normal renal tissues. 
 
Certain experiments were done to control the quality of the TMA and the integrity of the tissue 
specimens: 
 
• H&E-stained TMA sections were surveyed under the microscope to re-evaluate the quality 
and integrity of each tissue spot after generation of the TMA (Figure 9A).  
 
• To analyze the RNA integrity in the tissue spots, β-Actin oligonucleotide probes were 
hybridized to a TMA section directly after preparation of the TMA (Figure 9B).  
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• Since the sectioning of the TMA and the hybridization process might lead to loss of tissue 
material, each TMA sections was counterstained with Harris‘ hematoxylin after hybridization 
of the oligonucleotide probes to exclude tissue spots containing less than 60% representative 
cells from further analysis (Figure 9C).  
 
• To evaluate the specificity of the radioactive signal, slides were dipped into HypercoatTM 
LM-1 emulsion, which allows direct autoradiography of the TMA section (Figure 9D). 
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Figure 9: Control experiments to evaluate the quality of the tissues represented on the TMA and to assess
he specificity of the hybridization signal . t
 
H&E stained section of the TMA. (B) TMA hybridized with β-Actin probes. (C) TMA 
section counterstained with Harris‘ hematoxylin. (D) Magnification of TMA tissue spots after
autoradiography using HypercoatTM LM-1 solution. Black granules upon the cells are indicating the
localization of the radioactive signals. Based on those control experiments, certain tissue spots were excluded
from further analysis. For example, even though the morphology and amount of the tissue spots in row g was
good (A and C) those samples had to be excluded from further analysis because the RNA quality was poor
(B). 
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Based on these control experiments, the maximal number of evaluable tissue spots was 48 of 
originally 73 tissue specimens (Table 5). In brief, up to 36 (of originally 51) cRCCs, 3 (of 4) 
pRCCs, 3 (of 4) chRCCs, 1 (of 2) oncocytomas, and 5 (of 12) normal renal tissues were still 
analyzable. 
 
 
Overview of RISH results 
 
Only those tissue spots showing mean sDens values ≥ 2-fold mean background sDens values 
were considered positive for gene expression. Based on this threshold value, 19 of the 25 selected 
candidate genes were analyzable by RISH because they showed expression in at least three tissue 
spots (Table 5). Six genes (CKS1B, CSPG2, FOSL1, HMGA1, TGFB1, and NR0B2) did not show 
measurable sDens values in any of the evaluable tissue spots. Those genes were, even after 
repetition of the hybridization experiments, not analyzable by RISH. 
 
Table 5: Gene expression frequencies in the subset of analyzable candidate genes. 
 
Gene 
Positive 
tissue spots  
(n) 1
Evaluable 
tissue spots 
(n) 2
Gene  expression 
frequency 
(%) 3
BSG 24 43 56 
BTG2 8 46 17 
CD74 42 43 98 
CD9 12 39 31 
CENPF 6 41 15 
CHES1 12 47 26 
CTSD 42 47 89 
EGR1 26 46 57 
FCGRT 7 48 15 
FN1 18 47 38 
GAS6 24 48 50 
ITGA3 3 47 6 
ITGA6 9 47 19 
ITGB8 35 48 73 
K-alpha-1 19 41 46 
LITAF 20 46 43 
PAI1 10 44 23 
TIMP3 34 48 71 
VIM 47 48 98 
1 Number of evaluable RCC and normal renal tissue spots with gene expression (mean sDens value ≥ mean 2-fold 
background value). 
2 Total number of evaluable RCC and normal renal tissue spots. 
3 Gene expression frequency: number of tissue spots positive for gene expression / total number of evaluable tissue 
spots. 
Results 
As shown in table 5, the number of tissues displaying visible signals varied strongly within the 
set of analyzable genes. For example, VIM and CD74 were expressed in almost 100% of the 
evaluable tissue spots whereas ITGA3 expression was merely detectable in 6% of the analyzable 
cases (Table 5).  
 
Figure 10 shows Phosphorimager displays of renal TMA sections after hybridization with 
oligonucleotide probes targeting different genes. 
 
F
 
igure 10: Phosphorimager displays of renal TMA sections after RISH. 
Each hybridization results in individual expression patterns indicating the specificity of the used probes. 
 
Gene expression frequencies in RCC subtypes and normal renal tissue 
 
Since expression of some genes might be linked to certain RCC subtypes, gene expression 
frequencies of the 19 analyzable genes were compared between different RCC subtypes and 
normal renal tissue (Table 6). FN1, ITGA3, PAI1, and BTG2 were expressed in cRCCs, the most 
common RCC subtype, but not in any of the other subtypes. However, the opposite case, not 
expressed in cRCC but expressed in any of the other RCC subtypes, has not been observed. 
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Table 6: Gene expression frequencies in RCC subtypes and normal renal tissue evaluated by 
RISH. 
 
 Expression frequency 1
Gene cRCC pRCC chRCC onco- cytoma 2
normal 
kidney 
BSG 15/32 1/2 3/3 1/1 4/5 
BTG2 4/35 0/2 0/3 0/1 4/5 
CD74 33/33 1/2 3/3 na 5/5 
CD9 6/29 0/2 3/3 na 3/5 
CENPF 4/33 0/1 0/2 na 2/5 
CHES1 5/35 0/3 3/3 1/1 3/5 
CTSD 32/36 1/2 3/3 1/1 5/5 
EGR1 19/35 0/3 2/3 1/1 4/4 
FCGRT 6/36 1/3 0/3 0/1 0/5 
FN1 16/36 0/2 0/3 0/1 2/5 
GAS6 14/36 1/3 3/3 1/1 5/5 
ITGA3 3/35 0/3 0/3 0/1 0/5 
ITGA6 5/35 0/3 3/3 1/1 0/5 
ITGB8 29/36 1/3 0/3 1/1 5/5 
K-alpha-1 15/33 0/1 2/2 na 2/5 
LITAF 10/35 1/2 3/3 1/1 5/5 
PAI1 9/35 0/2 0/1 0/1 1/5 
TIMP3 25/36 0/3 3/3 1/1 5/5 
VIM 36/36 2/3 3/3 1/1 5/5 
1 Expression frequency: number of tissue spots positive for gene expression / total number of evaluable tissue spots. 
2 na: non of the tissue spots was analyzable. 
Gene expression frequencies in cRCC and normal renal tissue 
 
Statistical analysis was only done with the results obtained for cRCC and normal renal tissue. In a 
first step, gene expression frequencies (number of tissue spots positive for gene expression / total 
number of evaluable tissue spots) were compared between cRCC and normal renal tissue. As 
indicated in table 7, ITGA3, FCGRT, and ITGA6 were detectable in cRCC tissue spots but not in 
normal renal tissue. In contrast, BTG2, CHES1, GAS6, and LITAF were significantly (p < 0.05) 
more frequently expressed in normal renal tissue than in cRCC. CD9 and EGR1 were also clearly 
more frequently expressed in normal renal tissue than in cRCC but this association did not reach 
significance (p < 0.1 but > 0.05). 
 
In a second step, gene expression frequencies in cRCC were correlated with pT category and 
tumor grade in the subset of cRCC. Significant associations were found for BTG2, CD9, and 
TIMP3.  
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Expression of BTG2 and CD9 was associated with tumor extension (pT category). BTG2 was 
merely expressed in organ-confined pT1/pT2 (4/24, 17%) cRCCs but not in advanced pT3 
tumors (0/11, 0%). Expression of CD9 was also only found in pT1/pT2 (6/20, 30%) lesions but 
not in any of the analyzable (0/9, 0%) pT3 tumors.  
In contrast, expression of TIMP3 was associated with tumor grade. TIMP3 mRNA expression 
was less frequently found in grade 3 (1/5; 20%) than in grade 2 (17/23; 74%) and grade 1 cRCCs 
(7/8; 88%; p = 0.03). 
 
Table 7: Gene expression frequencies in cRCC and normal renal tissue evaluated by RISH. 
  Expression frequency 1
cDNA 
microarray 2 Gene 
normal renal 
tissue 
(n) 3
% cRCC (n) 3 % p-value 
4
CENPF 2/5 40 4/33 12 n.s. 
FN1 2/5 40 16/36 44 n.s. 
ITGA3 0/5 0 3/35 9 - 
ITGB8 5/5 100 29/36 81 n.s. 
K-alpha-1 2/5 40 15/33 45 n.s. 
PAI1 1/5 20 9/35 26 n.s. 
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VIM 5/5 100 36/36 100 n.s. 
BSG 4/5 80 15/32 47 n.s. 
BTG2 4/5 80 4/35 11 0.0003 
CD74 5/5 100 33/33 100 n.s. 
CD9 3/5 60 6/29 21 0.07 
CHES1 3/5 60 5/35 14 0.02 
CTSD 5/5 100 32/36 89 n.s. 
EGR1 4/4 100 19/35 54 0.08 
FCGRT 0/5 0 6/36 17 - 
GAS6 5/5 100 14/36 39 0.01 
ITGA6 0/5 0 5/35 14 - 
LITAF 5/5 100 10/35 29 0.002 
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TIMP3 5/5 100 25/36 69 n.s. 
1 Expression frequency: number of tissue spots positive for gene expression / total number of evaluable tissue spots. 
2 Gene expression pattern in preceding cDNA microarray experiments. 
3  Number of tissue spots with gene expression / total number of evaluable tissue spots. 
4  p-value was calculated using Chi-square analysis; n.s.: not significant. 
 
 
Gene expression levels in cRCC and normal renal tissue 
 
In order to quantitate mRNA expression levels in the tissues on the TMA, the raw sDens values 
(as measured by the Phosphor imager instrument) were utilized. Quantification is of particular 
Results 
50 
interest for those genes showing expression in both, tumor and normal tissues since the level of 
mRNA expression could be more important than the bare precence of the transcript. Here again, 
statistical analysis was done for the subset of cRCCs and normal renal tissues only.  
Significant associations were found for VIM and CD74. VIM was stronger expressed in cRCC 
than in normal renal tissue (p = 0.04). CD74 was stronger expressed in advanced pT3 tumors than 
in organ-confined pT1/pT2 tumors (p = 0.03). 
 
3.3 Molecular studies on BTG2 to evaluate its importance for cRCC biology 
 
In the second part of this thesis one gene was selected from preceding cDNA and tissue 
microarray experiments to further study its impact on cRCC biology. 
 
BTG2 was chosen for further studies because: 
 
• cDNA microarray analysis revealed significantly reduced BTG2 mRNA expression levels in 
all analyzed cRCC cell lines compared to normal renal tissue (Figure 11A). 
 
• RISH analysis showed that BTG2 was significantly less frequently expressed in primary 
cRCCs than in normal renal tissue (Figure 11B) thus corroborating the findings of the cDNA 
microarray hybridizations. 
 
• Melamed et al. (124) found strong BTG2 protein expression in normal epithelial cells of renal 
proximal tubuli from which cRCC arise (1) strongly suggesting that loss of BTG2 expression 
might be of great importance for renal tumor biology. 
Results 
Figure 11: BTG2 mRNA expression on cDNA and tissue microarrays. 
 
(A) BTG2 mRNA expression in cRCC cell lines and in normal renal tissue as assessed by  cDNA
microarray analysis. Magnifications of the BTG2 and G3PDH (reference gene) cDNA spots after
hybridization are shown in the lower pannel. BTG2 was strongly expressed in normal renal tissue but
nearly undetectable in all analyzed cRCC cell lines. (B) BTG2 mRNA expression in primary cRCC and in
normal renal tissue evaluated by RISH. BTG2 mRNA expression is detectable in 4 of 35 analyzable
cRCCs (indicated by circles) and in 4 of 5 normal renal tissues (indicated by a rectangle). Reference genes
G3PDH and β-Actin were used as positive controls (A, B). 
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3.3.1 Northern blot analysis 
 
Confirmation of cDNA microarray results 
 
To confirm the results obtained for BTG2 with the cDNA microarray experiments, single-
stranded 32P labeled DNA probes for BTG2 and G3PDH were hybridized to polyA+ mRNA of all 
four cRCC cell lines, normal renal tissue, and lymphocytes (positive control). BTG2 transcripts  
were detected at the expected size of 2.7 kb (representative BTG2 mRNA sequence under gene 
bank accession number NM_006763 at the NCBI homepage) in normal renal tissue and the 
positive control but not in any of the analyzed cRCC cell lines (Figure 12). In contrast, G3PDH 
mRNA was found in all analyzed samples at the expected size of 1.3 kb (representative G3PDH 
mRNA sequence under gene bank accession number NM_002046 at the NCBI homepage). 
(1.3 kb) 
(2.7 kb) 
Figure 12: Northern blot analysis of BTG2 to confirm cDNA microarray results. 
 
BTG2 mRNA expression was detectable as a single band at 2.7 kb in human lymphocytes (+) and normal renal tissue
(NRT) but not in cRCC cell lines (1 = Caki-1, 2 = Caki-2, 3 = 786-O, and 4 = 769-P) after 4 h exposition. G3PDH
was used as positive control. 
 
Evaluating specificity of BTG2 oligonucleotide probes 
 
To ensure the specificity of the BTG2 oligonucleotide probe used on the renal TMA, 32P labeled 
oligonucleotide probes for BTG2 (the same that were used in the RISH experiments) were 
hybridized to total RNA from human lymphocytes. A single band at 2.7 kb (representative BTG2 
mRNA sequence under gene bank accession number NM_006763 at the NCBI homepage) 
confirmed the specificity of the oligonucleotides for the BTG2 mRNA sequence (Figure 13). 
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BTG2 mRNA 
(2.7 kb)  
 
 
 Figure 13: Northern blot analysis of BTG2 to confirm specificity of oligonucleotide probes used in 
the RISH experiment. 
 
A strong and specific signal for BTG2 was obtained after an exposition time of 12 h. 
 
 
 
3.3.2 BTG2 mRNA expression in primary cRCC and normal renal tissue evaluated by 
quantitative RT-PCR 
 
BTG2 mRNA amounts were determined in a subset of primary cRCC and normal renal tissues by 
quantitative RT-PCR using the LightCycler technology.  
 
Calibration of RT-PCR 
 
To calibrate RT-PCRs, standard curves for BTG2 and G3PDH (reference) were established. For 
this purpose, serial dilutions of in vitro generated BTG2 and G3PDH mRNA were prepared. 
BTG2 and G3PDH PCR products were cloned into pGEM®-T easy vectors (Figure 14A). To 
generate run-off in vitro transcripts, plasmid DNA was digested with appropiate (SphI or PstI) 
restriction enzymes (Figure 14A). Run-off in vitro transcripts (sense strand) of BTG2 and 
G3PDH were generated from the linearized plasmid DNA (Figure 14B).  
Figure 14: Generation of in vitro transcribed BTG2 and G3PDH mRNA using the pGEM Teasy vector. 
(A) Gel electrophoresis of pGEM®-T easy plasmid DNA containing BTG2 (1) and G3PDH (2) PCR
products before (1 and 2) and after linearization with SphI (3 and 4) and PstI (5 and 6). M = DNA size
marker. (B) In vitro generated run-off transcripts of BTG2 (1) and G3PDH (2). M = RNA size marker. 
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Serial dilutions of both in vitro generated transcripts were reverse transcribed. First strand cDNA 
synthesis products were amplified on the LightCycler (Figure 15). Standard curve slopes were –
3.718 for BTG2 and –3.763 for G3PDH resulting in PCR efficiencies (E) of 1.86 and 1.84, 
respectively (Figure 15A).  
Melting curve analysis confirmed specificity of PCR reactions. Melting of BTG2 and G3PDH 
PCR products resulted in single melting-peaks for BTG2 and G3PDH (Figure 15B).  
 
E = 1.84 
G3PDH 
BTG2 
E = 1.86 
G3PDH 
BTG2  
 
 
 
 
Figure 15: Calibration of quantitative RT-PCR. 
 
(A) Standard curves for BTG2 and G3PDH; nc = negative control. (B) Melting curve analysis of BTG2 and 
G3PDH indicating the specifity of both PCR reactions. Unspecific primer-dimers occured in negative 
controls (nc) and in the lowest concentration of G3PDH template (indicated by arrowhead) only. 
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Quantification of BTG2 in primary cRCCs and normal renal tissues 
 
BTG2 mRNA expression levels were analyzed in 42 fresh-frozen primary cRCC and 17 normal 
renal tissues. BTG2 mRNA expression was significantly stronger in normal renal tissue than in 
cRCC. Mean BTG2 mRNA copy numbers were 1.5 x 106  per µg total RNA (range:1.9 x 105 – 3.7 
x 106)  in cRCC and 9 x 106 per µg total RNA (range: 2.1 x 106 – 3.9 x 107) in normal renal tissue 
(p < 0.0001; Figure 16A). Mean G3PDH mRNA copy numbers were 42.6 x 106 per µg total RNA 
(range:9.5 x 106 – 9.8 x 107)  in cRCC and 32.5 x 106 per µg total RNA (range: 8.3 x 106 – 4.9 x 
107) in normal renal tissue (p = 0.084; Figure 16A). BTG2/G3PDH mRNA copy number ratios 
were calculated to normalize for differences in RNA quality and quantity. Mean BTG2/G3PDH 
ratios were 0.043 (range: 0.0065 – 0.18) in cRCC and 0.288 (range: 0.073 – 0.84) in normal renal 
tissue (p<0.0001; Figure 16B). 
p < 0.0001
p < 0.0001
p = 0.084
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
BTG2 copies G3PDH copies
cRCC
normal
0
0.1
0.2
0.3
0.4
0.5
0.6
cRCC normal
cRCC
normal
F
 
igure 16: Quantitative mRNA expression analysis of BTG2 and G3PDH. 
(A) Mean BTG2 and G3PDH mRNA copy numbers in primary cRCCs and normal renal tissues. mRNA copy
numbers are given in Mio copies per µg total RNA. (B) Mean BTG2/G3PDH mRNA copy number ratios in
primary cRCCs and normal renal tissues. 
 
BTG2 mRNA expression was also correlated with tumor extension (pT category) and tumor 
grade in the subset of cRCCs. There was no association between BTG2 expression and pT 
category or tumor grade (Figure 17A and B). 
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igure 17: BTG2 mRNA expression in association with pT category and tumor grade in cRCC. 
(A) BTG2 mRNA expression and pT category. (B) BTG2 mRNA expression and tumor grade. BTG2 mRNA 
expression is given as BTG2/G3PDH mRNA copy number ratio. 
 
 
3.3.3 Modulation of BTG2 mRNA expression in cRCC cell lines 
 
TPA treatment of cRCC cell lines 
 
The phorbolester TPA has been shown by other groups (125, 126) to be a potent inducer of BTG2 
expression in HeLa cells and murine cell lines of different origin. Because BTG2 mRNA 
expression is significantly reduced in cRCC cell lines and primary cRCC the question arises 
whether BTG2 mRNA expression could be induced by TPA in cRCC cell lines. 
 
Caki-1, Caki-2, 786-O, 769-P, and HeLa (positive control) cells were treated with various 
concentrations of TPA. BTG2 and G3PDH mRNA copy numbers were determined by 
quantitative RT-PCR on the LightCycler. BTG2 mRNA expression in untreated cRCC cell lines 
were comparable to those obtained for primary cRCC (Table 8). Expression of G3PDH mRNA 
was not significantly affected by TPA in any cell line (Figure 18). Therefore, BTG2 to G3PDH 
mRNA copy number ratios were calculated to normalize for differences in RNA quality and 
amount (Table 8). According to these ratios, HeLa cells showed an up to 15-fold increase of 
BTG2 mRNA expression after addition of TPA (Figure 19). In contrast, BTG2 mRNA expression 
alterations upon TPA treatment were very weak or even not detectable in cRCC cell lines. 
Strongest response to TPA treatment was obtained for Caki-1 cells, which showed up to 2.4-fold 
increased BTG2 mRNA expression levels. There was no association between TPA concentration 
and BTG2 mRNA expression alteration in any cell line (Figure 19). 
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Table 8: BTG2 and G3PDH mRNA copy numbers in TPA treated cell lines. 
 
Cell line Treatment 1 BTG2 2 G3PDH 2 Ratio 3
HeLa T0 0.52 128 0.0041 
 25 ng TPA 6.58 106 0.0621 
 50 ng TPA 6.92 110 0.0629 
 75 ng TPA 7.26 121 0.0600 
 100 ng TPA 6.76 109 0.0620 
 0.01% DMSO 1.14 121 0.0094 
Caki-1 T0 0.63 117 0.0054 
 25 ng TPA 1.53 127 0.0120 
 50 ng TPA 1.49 115 0.0130 
 75 ng TPA 1.43 104 0.0138 
 100 ng TPA 1.23 106 0.0116 
 0.01% DMSO 0.33 103 0.0032 
Caki-2 T0 0.78 229 0.0034 
 25 ng TPA 0.85 174 0.0049 
 50 ng TPA 0.89 171 0.0052 
 75 ng TPA 1.12 216 0.0052 
 100 ng TPA 0.98 173 0.0057 
 0.01% DMSO 0.65 156 0.0042 
786-O T0 0.15 81.3 0.0019 
 25 ng TPA 0.29 118 0.0024 
 50 ng TPA 0.27 76.3 0.0036 
 75 ng TPA 0.23 99.6 0.0023 
 100 ng TPA 0.26 119 0.0022 
 0.01% DMSO 0.15 108 0.0014 
769-P T0 0.60 143 0.0042 
 25 ng TPA 0.50 119 0.0042 
 50 ng TPA 0.55 126 0.0043 
 75 ng TPA 0.86 182 0.0047 
 100 ng TPA 0.70 147 0.0048 
 0.01% DMSO 0.52 122 0.0042 
1 T0 = basal mRNA copy numbers (prior addition of TPA/DMSO). 
2 BTG2 and G3PDH mRNA copy numbers are given in Mio copies/µg total RNA. 
3 BTG2/G3PDH mRNA copy number ratio. 
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Figure 18: G3PDH mRNA expression alterations upon TPA treatment. 
 
Expression alterations are given in ± x-fold relative to basal G3PDH mRNA expression (prior addition of 
TPA/DMSO) in the respective cell line. no change: G3PDH mRNA expression in TPA/DMSO treated 
culture equals basal G3PDH mRNA expression. 
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igure 19: BTG2 mRNA expression change upon TPA treatment. 
BTG2 mRNA copy numbers were normalized to G3PDH mRNA copy numbers. Expression alterations are 
given in ± x-fold relative to basal BTG2/G3PDH mRNA copy number ratios (prior addition of TPA/DMSO) 
in the respective cell line. no change: BTG2 mRNA expression in TPA/DMSO treated culture equals basal 
BTG2 mRNA expression. 
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BTG2 mRNA expression and cell density 
 
BTG2 mRNA expression was found by other groups (127, 128) to be absent in exponentielly 
growing cell cultures but abundant in quiescent cells. For this reason, BTG2 mRNA expression 
was analyzed in association with cell density in cRCC cell lines. Caki-1, Caki-2, 786-O, and 769-
P cells were seeded at different densities and BTG2 and G3PDH mRNA copy numbers were 
assessed by quantitative RT-PCR 48 h after plating (table 9). Since G3PDH mRNA expression 
was not significantly linked to cell density (figure 20), BTG2 to G3PDH mRNA copy number 
ratios were calculated to normalize for differences in RNA quality and amount (table 9). BTG2 
mRNA expression was associated with increasing cell density in Caki-2, 786-O, and 769-P but 
not in Caki-1 cells (figure 21).  
 
 
Table 9: BTG2 and G3PDH copy numbers in association with cell density. 
 
Cell line Cell density 1 BTG2 2 G3PDH 2 Ratio 3
Caki-1 low 0.94 ± 0.01 189 ± 24 0.0050 ± 0.0001 
 medium 1 ± 0.03 205 ± 1 0.0049 ± 0.0002 
 high 0.97 ± 0.19 284 ± 60 0.0034 ± 0.0001 
Caki-2 low 0.45 ± 0.09 191 ± 30 0.0023 ± 0.0001 
 medium 0.65 ± 0.06 229 ± 29 0.0029 ± 0.0001 
 high 0.9 ± 0.11 209 ± 14 0.0043 ± 0.0002 
786-O low 0.16 ± 0.01 119 ± 13 0.0014 ± 0.0001 
 medium 0.23 ± 0.006 111 ± 1 0.0021 ± 0.0001 
 high 0.61 ± 0.02 102 ± 2 0.0060 ± 0.0003 
769-P low 0.33 ± 0.05 145 ± 35 0.0023 ± 0.0002 
 medium 0.45 ± 0.13 159 ± 27 0.0028 ± 0.0003 
 high 0.59  0.07 154 ± 3 0.0038 ± 0.0004 
1 low = initial cell number 1 x 105/well; medium = initial cell number 2 x 105/well; high = initial cell number 5 x 
105/well. 
2 BTG2 and G3PDH mRNA copy numbers are given in Mio copies/µg total RNA. 
3 BTG2/G3PDH mRNA copy number ratio.
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igure 20: G3PDH mRNA expression and cell density. 
G3PDH mRNA expression alterations are given in ± x-fold relative to cultures with lowest cell densities 
(initial cell number: 1 x 105 cells/well). no change: G3PDH mRNA expression in cultures with medium/high 
cell densities equals G3PDH mRNA expression in cultures with lowest densities. 
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igure 21: BTG2 mRNA expression and cell density. 
BTG2 mRNA copy numbers were normalized to G3PDH mRNA copy numbers. Expression alterations are 
given in ± x-fold relative to normalized BTG2 mRNA expression levels in cultures with lowest cell densities 
(initial cell number: 1 x 105 cells/well). no change: BTG2 mRNA expression in cultures with medium/high 
cell densities equals BTG2 mRNA expression in cultures with lowest densities. 
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4 Discussion 
 
4.1 Combination of cDNA and tissue microarray technologies for the identification of 
cRCC relevant genes 
 
General and specific aspects of cDNA and tissue microarrays 
 
DNA microarray technology has become one of the most popular platforms for performing global 
gene expression analysis in cancer. Commercially available cDNA microarrays mainly differ in 
the structure of the target sequences (e. g. cDNA or oligonucleotides), the support on which DNA 
targets are immobilized (nylon membrane, plastic, glass), and the mode of detection (radioactive 
or fluorescent). Although, the range of cDNA microarrays is diverse the advantages and 
disadvantages are very similar. Most advantageously features of cDNA microarrays are that they 
allow fast and quantitative expression profiling of thousands of genes in one experiment and that 
the identity of the arrayed genes is known a priori, in contrast to other expression screening 
methods (i. e. differential display RT-PCR), rendering time-consuming identification methods 
unnecessary. Disadvantages are (i) a possibly high number of false-positive signals due to 
unspecific hybridization reactions, (ii) requirement of large amounts of high quality RNA and 
(iii) high costs. Due to the vast number of arrayed gene sequences, cDNA microarrays produce 
large amounts of data which have to be handeled using bioinformatic tools. One of the major 
challenges of DNA microarray technology is to distinguish between „real“ and „false“ signals. 
This problem is addressed by applying stringent criteria for identifying gene expression 
alterations and confirming cDNA microarray results by independent approaches, e. g. Northern 
blot and quantitative RT-PCR (129, 130). 
 
In this study, AtlasTM Human Cancer 1.2 arrays (BD Clontech) were used. Compared to other 
microarrays, these arrays are rather small since they contain „only“ 1176 different cDNA 
sequences. However, AtlasTM cDNA microarrays have considerable advantages:  
 
• The selection of the arrayed sequences by the manufacturer was done with the focus on genes 
suggested to be involved in tumorigenic pathways. Thus, AtlasTM cDNA microarrays enable 
to concentrate on human cancer relevant genes. 
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• The use of 32P labeled cDNAs offers the most sensitive method for measuring gene 
expression (129). 
 
• The size of target gene cDNA fragments varies between 200-600 bp resulting in a high 
hybridization efficiency. 
 
• cDNA probes are generated with sequence specific primers leading to a high signal 
specificity. 
 
• In contrast to glass microarrays, Atlas cDNA microarrays are reusable (up to three times) and 
less expensive. 
 
Using AtlasTM Human Cancer 1.2 microarrays, a total number of 71 differentially expressed 
genes (at least 2-fold expression changes in at least two cRCC cell lines compared to normal 
renal tissue) were determined. The number of identified genes is comparable with those 
published by other groups using the same arrays for studying expression alterations in squamous 
cell carcinoma of head and neck, papillary thyroid carcinoma, and gastric cancer (131-133). 
Importantly, the set of isolated genes are differing in all studies indicating that uncovered 
expression alterations are tumor specific and thus are argueing for the reliability of AtlasTM 
cDNA microarrays. 
 
One of the bottle necks in cancer research is determining the clinical relevance of candidate genes 
uncovered by cDNA microarray analysis. Our recently developed TMA technology, which 
allows simultanous analysis of genes of interest in a large sample collective, has been designed to 
facilitate such studies (115). It has already been demonstrated by different groups that TMAs are 
optimally suited to evaluate the clinical significance of genes identified by cDNA microarray 
experiments (117-120).  
 
However, TMAs generated from archival, paraffin embedded tissue material have limitations. 
Processing of tissues in a routine histopathological laboratory often takes many hours causing 
partial or complete degradation of particularly RNA. Furthermore, formalin, which is routinously 
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used for tissue fixation, chemically modifies proteins and nucleic acids (134, 135) impeding the 
binding of antibodies and hybridization probes to their target molecules. As consequence, gene 
expression analysis using formalin-fixed, paraffin-embedded tissue is often very difficult or even 
impossible.  
 
Unfixed, fresh-frozen tissues would generally be superior for molecular analysis since quality and 
quantity of target molecules remain rather unaffected. Using a technology where tissues and 
recipient blocks are permanently kept below –20°C during TMA construction we were able to 
generate TMAs from snap frozen tissue specimens. A similar method was published at the same 
time when we were establishing this procedure at our institute two years ago (116).  
 
The use of frozen TMAs enabled us to perform mRNA gene expression analysis in numerous 
tissue specimens. Twenty-five genes, which were significantly differentially expressed (at least 4-
fold expression alteration in at least two cRCC cell lines compared to normal renal tissue) on the 
cDNA microarrays, were further studied by RISH on TMAs generated from frozen primary 
RCCs and normal renal tissues. It is of note, in comparison to paraffin TMAs, manufacturing and 
sectioning of frozen TMA is much more problematic since the tissue has to be kept frozen during 
the whole process to avoid RNA degradation. Furthermore, a special adhesive-coated tape 
system, which improves the sectioning of the TMA and helps to keep the tissue spots on the 
TMA section, was not applied for our “first generation” frozen TMAs. This lead to a rather high 
percentage (in average 38%) of tissue spots, which were lost during the sectioning and 
hybridization process. Despite these unwanted side effects 19 of 25 genes were successfully 
analyzed by RISH. Only six genes (CKS1B, CSPG2, FOSL1, HMGA1, TGFB1, and NR0B2) did 
not show any expression neither in the primary tumors nor in the normal renal tissues. Possible 
explanations for the observed discrepancies are:  
 
• Human cancer cell lines are frequently used as model for neoplastic disease. The high amount 
of high-quality RNA, yielded from cell lines, makes them superior to tissue material for 
expression analysis using cDNA microarrays. However, it has been shown that gene 
expression patterns of cell lines may differ more or less from those obtained for primary 
tumors since some genes become activated or deactivated through the culturing process, 
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growth factors in the medium, and adaption to culture enviroment (136-138). Thus, some 
gene alterations uncovered in this study might be cell culture artefacts. 
 
• Since the absolute number of mRNA target sequences in a 0.6 mm diameter tissue spot on the 
TMA is below the number of specific cDNA sequences present in a cDNA microarray spot 
some genes showing weak expression on the cDNA microarray remain undetected by RISH. 
 
Using a combination of cDNA and frozen tissue microarray analysis, five genes (VIM, CD74, 
CHES1, LITAF, and BTG2) have been identified which might be cRCC associated. The possible 
roles of VIM, CD74, CHES1, and LITAF in cRCC biology will be discussed in the following 
sections. BTG2, which appeared to be the most interesting candidate gene, was chosen for further 
studies. These results will be discussed in sectiom 4.2. 
 
VIM 
 
VIM (Vimentin), which is coding for an intermediate filament protein of the cytoskeleton, was 
clearly stronger expressed in cRCC cell lines and primary cRCC compared to normal renal tissue. 
Overexpression of VIM in cRCC cell lines and tissues was recently described by two other groups 
who also used cDNA microarrays for identification of renal tumor relevant genes (117, 139). 
Using paraffin TMA technology it was furthermore demonstrated that VIM protein expression is 
significantly associated with poor patient prognosis independent of tumor grade and stage (117). 
These data clearly show that potential prognostic tumor markers may be identified with cDNA 
microarrays. 
 
CHES1 
 
Reduced CHES1 mRNA expression was seen in cRCC cell lines and primary cRCCs. CHES1 is a 
member of the family of forkhead/winged transcription factors. Although, the biological function 
of CHES1 is yet unclear, certain lines of evidence indicate that this gene might be involved in 
DNA damage induced cell cycle arrest (140). Thus, reduced expression levels of CHES1 might 
result in genomic instability, which is one of the hallmarks of human cancer (141, 142). Recently, 
a homozygous missense mutation in CHES1 in a colon cancer cell line (143) and reduced 
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expression of CHES1 mRNA in gastric cancer (133) have been described indicating an important 
role of this gene in some human cancers. 
 
LITAF 
 
Similar to CHES1, LITAF showed reduced expression levels in cRCC cell lines and primary 
cRCCs. LITAF is involved in the activation of the human TNF-alpha gene (144) which encodes a 
multifunctional cytokine capable of inducing apoptosis by binding to TNF receptors (145, 146). 
Impaired mRNA expression of LITAF might contribute to renal tumorigenesis by delaying cell 
death. 
 
CD74 
 
Interestingly, CD74 mRNA expression was absent in cRCC cell lines but was detectable in 
primary cRCCs with expression levels similar to normal renal tissue. CD74 plays an important 
role in processing/maturation of MHC class II molecules. Through association with the latter, 
CD74 prevents untimely peptide loading of the premature MHC class II molecule and ensures 
correct trafficking to the intracellular peptide loading compartement. In contrast to MHC class I, 
which is expressed on almost all cell types, MHC class II was originally thought to be 
predominantly expressed on cells that present antigenes to CD4+ T cells like macrophages, 
monocytes, dendritic cells, and B lymphocytes (reviewed in (147)) suggesting that CD74 is also 
exclusively expressed in these cells.  
However, recent reports demonstrated that both, MHC class II and CD74, are also expressed in 
various primary human cancers, e. g. colorectal, head and neck, stomach, and renal tumors (148-
153). By IHC, Young et al. (139) recently found strong CD74 expression in primary cRCC cells 
and tumor associated stromal and endothelial cells in 65% of the analyzed primary cRCCs. 
As shown by RISH analysis on primary cRCCs, high CD74 expression levels were significantly 
associated with high pT category. This observation suggests a potential role of CD74 for tumor 
progression. Due to the biological function of CD74 one might speculate that increased 
expression of CD74 may help tumor cells to escape from the immune system by blocking peptide 
loading of MHC class II, thus preventing tumor antigen presentation on the cell surface. Results 
from other studies are supporting the theory that CD74 might have “oncogenic” properties in 
cRCC biology: (i) CD74 is localized on chromosome 5q, which is frequently gained in cRCC 
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(56, 154, 155); (ii) strong and frequent CD74 protein expression in primary cRCC was recently 
described (139, 149), and (iii) increased CD74 protein expression is also associated with tumor 
progression in colon and gastric cancers (153, 156). Therefore, CD74 is a potential candidate 
gene for cRCC biology and further studies would be worthwhile. 
 
4.2 BTG2 – a new candidate gene for renal tumor biology? 
 
cDNA and tissue microarray experiments demonstrated strong BTG2 mRNA expression in 
normal renal tissue but reduced or absent expression in cRCC cell lines and primary tumors. 
Recently, Melamed et al. (124) showed that BTG2 protein is strongly expressed in epithelial cells 
of the proximal tubulus of the kidney from which cRCC arise (1). These findings strongly 
suggest that BTG2 is important for renal tumorigenesis. 
 
Biological function of BTG2 
 
BTG2 (also known as TIS21 or PC3) was first described in 1991 and belongs to a gene family 
consisting of six members (BTG1, BTG2, PC3B, ANA, TOB, and TOB2), all of which having 
antiproliferative properties (reviewed in (157)). BTG2 was cloned from nerve growth factor 
(NGF) treated PC12 cells suggesting that this gene might be of importance for neuronal 
differentiation (126). Further studies revealed that the impact of BTG2 on neurogenesis is through 
cell cycle control since forced expression of BTG2 in PC12 resulted in G1/S arrest (158) and 
BTG2 is expressed in neuroblasts undergoing the last proliferation before differentiating into 
postmitotic neurons (159, 160). The cell cycle regulatory function of BTG2 is not restricted to 
neuronal cells. Forced expression of BTG2 resulted in cell cycle arrest at G1/S in NIH3T3 and 
293 cells (158, 161, 162). Furthermore, BTG2 is capable of inducing cell cycle arrest at the G1/S 
and also the G2/M checkpoint upon DNA damage in a p53 dependent manner (127, 163, 164).  
Besides p53 and NGF also fibroblast- and epidermal growth factor (FGF and EGF), the 
phorbolester TPA, Interleukin-6, and cAMP are able to induce BTG2 expression (125, 126, 158). 
It is therefore concluded that a number of different signal transduction pathways turn on or 
enhance transcription of this gene. 
 
In accordance, by sequencing the BTG2 gene putative binding sites for several transcription 
factors including AP-1, GATA-1, NFkappaB, CREB, and p53 were identified (Figure 22; (164)). 
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Figure 22: Genomic sequence of BTG2 (Duriez et al. 2002) 
 
The molecular mechanisms how BTG2 exerts its cell cycle regulatory function are not well 
understood. BTG2 has been shown to interact with transcription factors like Hoxb9 (165), hCAF1 
and CALIF (166) and modulate their activity indicating that BTG2 functions as a transcriptional 
regulator. It was also demonstrated that BTG2 binds to protein-arginine N-methyltransferase 1 
(PRMT1) resulting in enhanced activity of PRMT1 (167, 168). Many of the target proteins of 
PRMT1 are involved in RNA processing, metabolism and transport (e.g. SPT5 (169), poly(A) 
binding protein II (170), ILF3 (171), hnRNP A2 (172), and Sam68 (173)) and also in chromatin 
organization (174) suggesting that BTG2 also plays a role in „pre-transcriptional“ and post-
transcriptional regulation steps. 
Thus, by interacting with various partners, BTG2 appears to have influence on almost all steps of 
transcription strongly suggesting that BTG2 excerts its cell cycle regulatory function by 
controlling transcription of the respective genes (Figure 23). 
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Figure 23: Probable mode of action of the negative cell cycle regulator BTG2. 
 
Recent findings are supporting the theory that BTG2 is involved in cell cycle arrest through its 
involvement in transcriptional regulation : 
 
• Guardavaccaro et al. demonstrated that cell cycle arrest at G1/S induced by forced BTG2 
expression relies on inhibition of cyclin D1 transcription and consequently accumulation of 
hypophosphorylated Rb protein (162). 
 
• Growth inhibition of wild-type p53 containing MCF-7 cells after genotoxic treatment was 
accompanied by increased methylation of histone IIA and enhanced BTG2 mRNA expression. 
In contrast, MCF-7 cells stably transfected with a dominant negative form of p53 that 
abrogates sequence-specific DNA binding of p53 did not show increasing BTG2 mRNA 
expression levels and enhanced methylation of histone IIA upon adriamycin treatment. These 
cells were unable to arrest cell cycle (163). 
 
• The negative cell cycle regulatory function of BTG2 is an important tumor suppressive 
property, which has been described for well known tumor suppressor genes, e. g. p53 (175), 
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pRB (176) or p16 (177). In addition, BTG2 participates in at least two cellular pathways (p53 
and pRb), which are of great importance for tumorigenesis (178, 179). 
 
BTG2 - a tumor suppressor candidate for cRCC? 
 
In an attempt to study the possible tumor suppressive role of BTG2 in renal tumorigenesis, the 
clinical impact of BTG2 expression alterations in primary cRCC was analyzed in a first step. In a 
second step, the expression regulation and cell cycle regulatory function of BTG2 were examined 
in cRCC cell lines. 
 
Because commercially available antibodies for BTG2 are not existing to date, correlation of 
BTG2 protein expression with pathological and clinical parameters in cRCC using our large 
paraffin renal TMA (contains more than 500 archival RCC tissues) was unfortunatly not possible. 
For this reason, BTG2 expression was studied on the mRNA level in 42 primary cRCCs and 17 
normal renal tissues using quantitative RT-PCR. Using this approach, the results obtained from 
cDNA microarray, RISH, and Northern blot experiments were confirmed. Normal renal tissues 
showed significantly stronger BTG2 mRNA expression levels than primary cRCCs. Although 
BTG2 expression was detectable in all tumor samples, primary cRCCs showed - compared to the 
mean, normalized BTG2 mRNA copy number of normal renal tissue - 6.7-fold (1.6-fold to 44-
fold) reduced BTG2 mRNA expression. Reduced BTG2 mRNA expression levels were not 
associated with high tumor grade or pT category suggesting that impaired BTG2 expression is 
rather an early event in renal tumorigenesis. 
 
To address the possible tumor suppressive function of BTG2 in renal cancer, the regulation of 
BTG2 mRNA expression was studied in cRCC cell lines. It has been shown that BTG2 is an 
immediate early response gene, whose transcription can be induced by the phorbolester TPA in 
human HeLa cells and also in a variety of rodent cell lines of different origin (125, 126). 
According to this, serveral AP-1 binding sites (which are also known as TPA response elements; 
TREs), are located in the promotor region of BTG2 ((164); Figure 22). These findings prompted 
us to investigate the inducibility of BTG2 expression by TPA in the cRCC cell lines Caki-1, 
Caki-2, 786-O, and 769-P. Among all tested cRCC cell lines, merely Caki-1 cells showed a 
response to TPA. However, compared to HeLa, the increase of BTG2 mRNA expression was 
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very weak (15-fold versus 2.3-fold). There are different explanations for the inability of cRCC 
cell lines to induce BTG2 expression upon TPA treatment: 
 
• Phorbolesters like TPA mainly excert their effects in cells by activating members of the 
protein kinase C (PKC) family (180, 181) but also by activating certain other receptors 
lacking kinase activity (reviewed in (182, 183)). Given the large number of PKC isotypes, 
which frequently show tissue specific expression patterns (184-188) and which have plenty of 
cellular substrates involved in many different biological processes (189), the reaction of cells 
upon phorbolester treatment may largely depend on the expression pattern of PKCs in this 
cell type. According to this, phorbolesters have been reported to enhance proliferation but 
also induce growth arrest, differentiation, and apoptosis in a variety of human cancer cell 
lines (190-193). Therefore, it is possible that discrepancies in the ability to induce BTG2 
expression upon TPA treatment in cervix carcinoma and cRCC cells are due to different 
TPA-target expression patterns in the respective cell lines. 
 
• The effect of TPA on BTG2 transcription activation is indirect and requires a signaling 
cascade acting as an intermediary. Alterations in this signaling cascade might occure in cRCC 
but not in cervix carcinoma cells resulting in impaired activation of BTG2 gene transcription 
in cRCC cell lines upon TPA treatment. 
 
• The BTG2 gene might directly be affected by inactivating mutations, hypermethylation of 
CpG islands located in the promoter (164), or deletion leading to constricted gene activity in 
cRCC cell lines. 
 
Whether the inability to induce BTG2 mRNA expression upon TPA treatment in cRCC cell line 
but not in cervix carcinoma cells is caused by natural physiological differences in both cell types 
or by pathological alterations in the analyzed cRCC cell lines remains to be clarified. 
 
Based on recent observations of other groups who showed that BTG2 expression is low in 
exponentially growing cell lines, whereas quiescent cells showed high BTG2 expression levels 
(127, 128) BTG2 mRNA expression was quantitatively analyzed in cRCC cultures with different 
cell densities. BTG2 mRNA expression was linked to increasing cell densities in Caki-2, 786-O, 
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and 769-P. The strongest association was found in 786-O cells, which showed slightly more than 
4-fold increased BTG2 mRNA expression in cultures with highest cell densities. Compared to 
this, the increase of BTG2 mRNA expression was rather weak in Caki-2 and 769-P (both less 
than 2-fold).  
 
It is of note that, although some of the cRCC cell lines are able to induce BTG2 upon certain 
stimuli, neither TPA nor high cell densities were able to raise BTG2 expression to the level 
observed in normal renal tissues. Downregulation of BTG2 mRNA expression might therefore be 
an important mechanism driving renal cancer development.  
 
The question arises, whether BTG2 is a new tumor suppressor gene candidate or whether reduced 
expression of BTG2 is merely a downstream-effect of impaired function of a signalling cascade. 
The inability of cRCC cell lines to enhance BTG2 mRNA expression upon cellular cues (TPA 
and cell density) to the levels obtained in normal renal tissue are a strong argument for a tumor 
suppressive function of BTG2 in cRCC.  
 
Already in 1971 Knudson postulated (194) - based on his studies on hereditary retinoblastoma - 
that two independent events, loss of one allele and mutation of the remaining allele, were needed 
to inactivate a given tumor suppressive gene resulting in malignant transformation. To date, this 
„two-hit“ hypothesis is generally accepted and indeed many tumor suppressor genes are 
inactivated by deletion of one allel and mutation or (more recently acknowledged) epigenetic 
silencing of the other allel (reviewed in (195-197)).  
 
A common deleted region was described in breast cancer spanning 1q23-32 (198), the latter 
including the BTG2 locus (127). Duriez et al. (164) has analyzed primary breast tumors and 
breast cancer cell lines for LOH at 1q32 and mutations in the two exons of the BTG2 gene to 
study whether the “two-hit” hypothesis for inactivation of a tumor suppressor gene holds true for 
BTG2 as well. They found LOH at 1q32 in 4 of 18 primary breast tumors. However, they were 
not able to identify any mutation in the BTG2 sequence argueing against the “classical” modus of 
a tumor suppressor gene inactivation.  
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In this context, it is noteworthy that for some tumor suppressor genes impaired function of 
merely one allele may also be enough to drive tumorigenesis (reviewed in (195)). This new class 
of so-called haploinsufficient tumor suppressor genes has been inferred from mouse models of 
human cancer. Recently it has been demonstrated that mice hemizygous (+/-) for tumor 
suppressor genes like p27Kip1 (199), p18(INK4c) (200), transforming growth factor-beta 1 (201), 
and also p53 (202), show a higher spontanous tumor rate than their homozygous (+/+) littermates 
and rapidly develop tumors when challenged with carcinogens. In all cases the remaining wild-
type allele remained unaffected.  
 
In accordance, FUS1, a candidate tumor suppressor gene, which was identified from a 630 kb 
deletion region in lung cancer (203), is infrequently mutated or methylated in lung cancer cell 
lines and primary lung tumors (204). Kondo et al. (204) recently demonstrated that forced 
expression of FUS1 leads to G1 arrest and growth inhibition in lung cancer cells suggesting that 
FUS1 is also a candidate for a haploinsufficient tumor suppressor gene. 
 
Another example for a potential haploinsufficient tumor suppressor gene is the transcription 
factor KLF5 at 13q21. Forced expression of KLF5 in breast and prostate carcinoma cell lines 
significantly inhibited growth of these cells. Although KLF5 is frequently deleted at one allele in 
breast and prostate carcinoma cell lines inactivating mutations or hypermethylation of the 
remaining allel are uncommon (205, 206).  
 
Current reports suggest that haploinsufficiency of tumor suppressor genes is caused by deletion 
of one allel whereas the other allel remains unaffected. As shown by CGH analysis, loss of 1q is 
a rare event in cRCC (see figure 2 (56)) speaking against the theory of a haploinsufficient tumor 
suppressor gene. However, one should take in account that CGH is a rather insensitive method 
detecting only those DNA sequence losses spanning more than 10 Mb (207). Using LOH analysis 
it would be possible to uncover very small deleted chromosomal segments at 1q. 
But even if BTG2 is not deleted at one allele in renal cancer, the loss of tumor suppressive 
properties of this gene due to haploinsufficiency is still an attractive model for cRCC. One might 
speculate that expression of some potential haploinsufficient tumor suppressor genes might be 
decreased not due to deletion but due to mutation or hypermethylation of one allele. Those genes 
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would remain undetected by CGH and LOH analysis but would attract attention in cDNA 
microarray experiments.  
 
Analyzing the mutation, methylation and LOH status of the BTG2 gene in renal cancer would 
clarify whether this gene is directly affected by inactivating events at one or even both alleles and 
could thus be regarded as a new potential tumor suppressor gene for renal carcinogenesis. 
 
Outlook 
 
In this thesis a combination of cDNA and tissue microarray technology was used to identify 
potential RCC relevant genes. The negative cell cycle regulator and potential tumor suppressor 
BTG2 was one of the most interesting candidate genes and we decided to further study the impact 
of this antiproliferative gene on renal carcinogenesis. As already mentioned, the experiments 
done in this thesis only allow to speculate about the role of BTG2 in cRCC biology. The impaired 
ability of cRCC cell lines to significantly enhance expression of BTG2 in response to increasing 
cell density strongly indicates that impaired function of this gene is of importance for renal 
tumorigenesis and that BTG2 might be a tumor suppressor for cRCC. As discussed above, tumor 
suppressor genes are generally inactivated by loss of function of both alleles (by deletion and 
mutation/hypermethylation or by deletion of both alleles) or, if they are haploinsufficient, by 
deletion of merely one allele. Thus, to prove whether BTG2 is a tumor suppressor for cRCC or 
not, the following experiments would be helpfull: 
 
• Methylation analysis of the BTG2 promotor in RCC cell lines and primary RCCs would show 
whether impaired BTG2 mRNA expression is a result of epigenetic silencing of the BTG2 
gene. 
 
• Sequence analysis of the BTG2 gene in RCC cell lines and primary RCC might show whether 
the function of this antiproliferative gene is impaired in renal tumors. 
 
• LOH analysis would show whether reduced BTG2 mRNA expression is based on deletion of 
one or even both alleles. 
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• Forced expression of BTG2 using appropiate vectors transfected into cRCC cell lines 
followed by monitoring the proliferation rate in transfected and non-transfected cells will 
show whether BTG2 is necessary for negative cell cycle regulation in cRCC cells as well. 
 
The large number of fresh frozen and formalin fixed renal tumors, which are stored in the 
tumorbanks of our institute can be used for the above mentioned experiments (Methylation- and 
mutation assays, LOH analysis) and will enable us to uncover potential associations between the 
obtained results and tumor related and clinical follow-up data. 
 
Generation of antibodies against BTG2 would allow us to study BTG2 protein expression levels 
and the distribution of BTG2 protein within malignant and normal renal tissue by IHC and 
Western blot analysis. Here again the large number of renal tissues stored in our tumorbanks and 
also the availability of a large renal TMA containing more than 500 different RCC and normal 
renal tissues will significantly facilitate the correlation of protein expression data with tumor and 
patient related information. 
 
Most tumor suppressor genes are not linked to a certain tumor type. Our group has constructed 
„multi-tumor“ TMAs containing thousands of different tissue core biopsies of almost all human 
cancers and corresponding normal tissues. RISH and IHC analysis on those TMAs might uncover 
other tumor types for which BTG2 might be of importance. 
 
4.3 Conclusion 
 
In this thesis, combined cDNA and tissue microarray analysis was performed to screen for genes 
differentially expressed in cRCC and normal renal tissue. Although, the cDNA microarrays were 
rather small (1176 genes) and the TMAs generated from frozen tissue specimens belonged to our 
first-generation TMA set, five genes (VIM, CD74, CHES1, LITAF, and BTG2) were uncovered, 
which might be of importance for cRCC biology. 
 
The identification of VIM and CD74, which have already been associated with renal cancer in 
previous reports, are corroborating the reliability of the cDNA and tissue microarray analysis in 
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this study. In contrast, CHES1, LITAF, and BTG2 have never been linked to renal cancer before 
and are thus new potential renal tumor relevant genes.  
Further experiments on the negative cell cycle regulator BTG2 strongly indicate that this gene 
might have tumor suppressor properties in cRCC biology because (i) cRCC cell lines and primary 
cRCCs showed significantly reduced BTG2 expression levels compared to normal renal tissue as 
assessed by quantitative RT-PCR; (ii) cRCC cell lines were unable to raise BTG2 mRNA 
expression to the levels obseved in normal renal tissue upon certain cues (TPA and increasing 
cell density). Allelic deletion, mutation and methylation analysis of the BTG2 gene and also re-
expression of BTG2 in cRCC cell lines will show whether BTG2 is a new renal tumor suppressor 
gene. 
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5 Appendix 
 
10 X MOPS: 
0.2 M 3-N-morpholino-propanesulfonic acid (MOPS) 
0.5 M sodium acetate 
0.01 M Ethylenediamine tetraacetic acid (EDTA) 
adjust pH to 7.0 with NaOH and autoclave 
 
20 X SSC: 
3 M NaCl 
0.3 M Na3citrate
.2H2O 
adjust pH to 7.0 with NaOH/HCl and autoclave 
 
50 X TAE (per liter): 
242 g Tris base 
57.1 ml glacial acetic acid 
37.2 g Na2EDTA
.2H2O 
 
LB/Agar plates supplemented with X-Gal and IPTG (per liter): 
15 g Agar 
10 g Bacto®-tryptone 
5 g Bacto®-yeast extract 
5 g NaCl 
adjust pH to 7.0 with NaOH and autoclave 
allow the medium to cool to 50°C before adding  
100 µg/ml Ampicillin 
80 µg/ml X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) 
0.5 mM IPTG (Isopropylthio-β-D-galactoside) 
pour 30-35 ml into 85 mm petri dishes 
 
LB-medium (per liter): 
10 g Bacto®-tryptone 
5 g Bacto®-yeast extract 
5 g NaCl 
adjust pH to 7.0 with NaOH and autoclave 
allow the medium to cool to 50°C before adding  
100 µg/ml Ampicillin 
 
Methylene-blue staining solution: 
0.03% methylene-blue 
0.3 M sodium acetate, pH5.2 
 
Northern blot wash solution I-III: 
prepared from 20 X SSC and 10% SDS stock solutions 
I: 2 X SSC/0.1 % SDS 
II: 0.2 X SSC/0.1 % SDS  
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III: 0.1 X SSC/0.1 % SDS  
 
Formamide prehybridization/hybridization (FPH) solution: 
25 ml 20 X SSC 
5 ml 100 X Denhardt solution (100 X Denhardt is: 10 g Ficoll 400, 10 g polyvinylpyrrolidone,  
10 g bovine serum albumin (BSA), H2O to 500 ml) 
50 ml Formamide 
10 ml Sodium dodecyl sulphate (SDS) 10% 
H2O to 100 ml 
 
RISH hybridization mix: 
50 ml Formamide 
20 ml 20 X SSC 
1 ml 100 X Denhardt solution (100 X Denhardt is: 10 g Ficoll 400, 10 g polyvinylpyrrolidone,  
10 g bovine serum albumin (BSA), H2O to 500 ml) 
10 ml 0.2 M NaPO4, pH 7.0 
10 g Dextran sulphate 
5 ml 20% N-Lauroylsarcosine Sodium salt (Sarcosyl) 
H2O to 100 ml 
 
Trypan blue: 
150 mM NaCl 
0.5% trypan blue 
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